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Abstract
RADIOPROTECTIVE CERIUM OXIDE NANOPARTICLES: MOLECULAR IMAGING
INVESTIGATIONS OF CONPS' PHARMACOKINETICS, EFFICACY, AND MECHANISMS
OF ACTION
By Philip Reed Wills McDonagh III, BS
A dissertation submitted in partial fulfillment of the requirements for the degree of Doctor of
Philosophy in Cancer and Molecular Medicine at Virginia Commonwealth University.
Virginia Commonwealth University, 2016
Director: Jamal Zweit, PhD, DSc
Professor, Department of Radiology
Director, Center for Molecular Imaging
Cerium oxide nanoparticles (CONPs) are being investigated for several anti-oxidant applications
in medicine. One of their most promising applications is as a radioprotective drug, an area of
research in need due to the severe side effects from radiation therapy. In this work, the potential
of CONPs as a radioprotective drug is examined using four criteria: favorable
biodistribution/pharmacokinetics, low toxicity, ability to protect normal tissue from radiation
damage, and lack of protection of tumor. The mechanisms of action of CONPs are also studied.
Biodistribution was determined in radiolabeled CONPs with surface coatings including citrate,
dextran T10-amine (DT10-NH2), dextran T10-polyethylene glycol (DT10-PEG), dextran T10sulfobetaine (DT10-SB) and poly(acrylic acid) (PAA), and compared to uncoated. 89Zr was
incorporated into CONPs for positron emission tomography (PET) imaging and ex vivo tissue
analysis in tumor bearing mice. Compared to uncoated [89Zr]CONPs, coated [89Zr]CONPs
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showed improved biodistribution, including significantly enhanced renal clearance of PAA[89Zr]CONPs. The toxicity of CONPs was evaluated in vitro and in vivo, with low toxicity at
therapeutic doses. After clinically mimetic radiation therapy, pre-treatment of mice with coated
and uncoated CONPs showed greater than 50% reduction of cell death in normal colon tissue,
comparable to the clinically available radioprotective drug amifostine. Tumor control after
irradiation of spontaneous colon tumors was unchanged with PAA-CONP pre-treatment, while
citrate, DT10-PEG, and uncoated CONP pre-treatment had slightly less tumor control. Xenograft
tumors were irradiated after pH normalizing treatment with sodium bicarbonate and PAA-CONP
pre-treatment. Treatment of these tumors showed slightly less tumor control than irradiation
alone or PAA-CONP plus irradiation, demonstrating that the acidic pH of the tumor
microenvironment may be the basis of preventing CONPs’ radioprotective properties in tumor.
These studies show that, among the variations of CONPs tested, PAA-CONP shows the most
promise for its good biodistribution and quick clearance, low toxicity, ability to protect normal
tissue, and lack of protection of tumor, meeting all the criteria set forth for an ideal
radioprotective drug. Further studies on the effects of pH on CONPs actions may further
elucidate their mechanisms of action, advancing them as a candidate for use as a radioprotective
drug during radiation therapy.
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Thesis Organization

This thesis is divided into seven chapters. The first chapter is a general introduction to the
project, including an overview of cerium oxide nanoparticles (CONPs) as a radioprotective drug,
the hypothesis being tested, and strategies to test that hypothesis. The second chapter discusses
the background and significance of the project, giving an overview of the rationale for the
research and the development of the many techniques used. The third chapter details the methods
used to accomplish the goals of the project. Chapter 4 gives the results of the research and
Chapter 5 discusses the impact of these results. Chapter 6 summarizes all the findings in
conclusion. Finally, Chapter 7 discusses future work as research continues with CONPs as
radioprotective drugs and are aimed towards applications in other medical areas and clinical
trials.
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1. Chapter 1 – General Introduction

1.1.

Radioprotective Drugs and Cerium Oxide Nanoparticles

The study of drug therapies to reduce side effects from radiation therapy is a promising area of
research for its implications on improving quality of life of patients and the curative effects of
cancer radiation therapy. Currently, very few drugs are available for treatment of radiation
therapy side effects, but many are being studied as the mechanisms of radiation cell damage and
methods to prevent them are being better understood. Agents that are able to prevent radiation
damage are likely to be antioxidant, with the ability to reduce radiation-produced radical species
and prevent them from damaging cellular components, especially DNA. An antioxidant agent
should have several qualities that would make it ideal for use as a radioprotective agent in the
setting of radiation therapy. These qualities include: 1) Favorable
biodistribution/pharmacokinetics – the agent should reach the tissue that would be damaged by
radiation, with proper clearance and higher uptake in normal tissues than cancerous tissue, 2)
Low toxicity – the agent should not cause more side effects than expected from radiation therapy,
3) Minimal protection of cancerous tissue – the radioprotective effects should be absent or
minimal in cancerous tissue so that the tumor control by the radiation treatment is not
significantly altered, and finally 4) Protection of normal tissue – the agent should reduce
radiation damage to normal cells in the area of radiation therapy to the point where side effects
can be reduced and quality of life can be improved. This projects aims to determine if cerium
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oxide nanoparticles (CONPs) meet these criteria and show promise for use in the clinic, using
molecular imaging techniques.

1.2.

Hypothesis and Aims

The hypothesis of this project is that CONPs are radioprotective in a pH dependent manner and
altering surface chemistry can improve pharmacokinetics and advance application to
reduce/prevent side effects in the setting of cancer patients treated with radiation therapy.

The aim of this research is to develop, characterize, and evaluate several coated cerium oxide
nanoparticles for their application as a radioprotective drug. The specific objectives of this
project are:

1. Optimize synthesis and characterization of coated and radiolabeled CONPs
2. Use molecular imaging to determine and compare biodistribution and pharmacokinetics
of coated and uncoated CONPs
3. Compare coated and uncoated CONPs in terms of in vivo radioprotection
4. Determine if CONPs’ radioprotection is dependent on pH environment

1.3.

Strategy

This project aims to examine cerium oxide nanoparticles (CONPs) as a potential radioprotective
agent using a variety of nanosynthesis, molecular imaging, and pre-clinical radiation therapy
techniques.

1.3.1. Synthesis of Coated CONPs
Utilizing the intrinsic ability to alter the surface chemistry of nanoparticles by addition of small
molecules or polymers, five coated CONPs will be tested and compared to uncoated CONPs.
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The five coatings on CONP will include citric acid/ethylenediaminetetraacetic acid (EDTA),
henceforth simplified to “citrate,” dextran T10-amine (DT10-NH2), dextran T10-polyethylene
glycol (DT10-PEG), dextran T10-sulfobetaine (DT10-SB), and polyacrylic acid (PAA). These
coatings will alter the size and surface charge of the nanoparticles, dependent on the properties of
the coating molecules, and will affect their biodistribution and pharmacokinetics accordingly.

1.3.2. Intrinsically Radiolabeled CONPs with 89Zr
CONPs’ biodistribution and pharmacokinetics will be examined through molecular imaging of
89

Zr radiolabeled CONPs for PET imaging and ex vivo biodistribution. The synthesis of CONPs

can be altered with the addition of 89ZrCl2 to intrinsically incorporate the isotope into the core of
the nanoparticles, as seen in Figure 1B.1 This method is more stable than the chelator model of
radiolabeling, seen in Figure 1A, preventing the release of isotope and corresponding loss of
coordinated radioactivity and nanoparticle concentration, and avoiding alteration of surface
chemistry. The 89Zr isotope is a clinically relevant PET imaging isotope and allows for both high
activity PET imaging, including dynamic scans which create a video of the distribution of the
nanoparticles over the first hour after injection, and ex vivo biodistribution to more precisely
measure uptake in specific organs.

Figure 1: A) External radiolabeling of nanoparticles using the radioactive chelator model, compared to B) the radiointrinsic model, which incorporates the radioactive isotope into the core of the nanoparticle. Reproduced from
Journal of Materials Chemistry B, Ref. 1, copyright 2014, with permission of The Royal Society of Chemistry.
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1.3.3. Pre-clinical Radiation Therapy and Colon Cancer Tumor Model
Mice with and without cancer are treated with CONPs and undergo clinic mimicking radiation
therapy to examine effects on normal and cancerous tissue. A small animal radiation research
platform (SARRP) is able to mimic clinical conformal radiation therapy in animal models. The
platform simulates doses, cell damage, and side effects produced by clinical radiation therapy by
delivery precision doses of radiation to collimated areas, guided by CT imaging. While normal
C57BL/6 mice are used to examine the results of radiation on normal tissue, a spontaneous colon
cancer tumor model was used to examine results of radiation on cancerous tissue. This model
better mimics the spontaneous tumors of cancer patients, compared to xenograft tumor bearing
mice. Response to therapy is monitored by apoptosis labeling of ex vivo colon slices and
[18F]FDG PET imaging to determine tumor metabolic activity.

1.3.4. Molecular Imaging of pH and Effects of Tumor
Microenvironment on CONP Radioprotection
The mechanisms of CONPs’ action will be examined in the context of the tumor
microenvironment (TME), specifically in regards to the acidic pH of tumors. In vivo imaging of
pH is a developing field, and an MR imaging technique utilizing a clinically available contrast
agent was used. This method utilizes chemical exchange saturation transfer (CEST) imaging to
selectively saturate several exchangeable protons in the contrast agent that have pH specific
response, allowing for concentration independent ratiometric pH mapping overlaid on MRI
images. This in vivo measurement of pH allows for the determination of pH effects in vivo using
baseline scans before irradiation of tumors. Tumor bearing mice can be treated with sodium
bicarbonate to alkalinize the tumor microenvironment and determine if a change in pH affects
how CONPs affect radiation damage to tumors.
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2. Chapter 2: Background and Significance

2.1.

Significance and Scope of Project

Over one and a half million people are expected to be diagnosed with cancer in 2016, with
almost six hundred thousand expected to die.2 While these are staggering numbers, the
contributions of early detection and advances in therapy have led to more than 14 million cancer
survivors currently in the United States and a 5 year survival rate that has increased by 20% in
the last 30 years.

The three main treatment options for cancer include surgical resection, radiation therapy, and
chemotherapy, but may also include hormone therapy, immune therapy, or targeted therapies that
specifically interfere with cancer growth. The appropriate therapy is determined by tumor type
and stage, which includes the extent of the primary tumor (T), spread to and number of involved
lymph nodes (N), and the presence or absence of metastasis (M). If metastasis is detected,
resection of the tumor is less likely to be possible as a curative option, and radiation therapy and
chemotherapy become the most viable options for curative therapy. Despite advances in drug
targeting and conformal radiation therapy, these treatments can have serious side effects due to
their non-specific damage which causes destruction of normal tissues. These side effects can
drastically decrease the quality of life of patients undergoing therapy. It is therefore an important
area of research in discovering treatments that may prevent the collateral normal tissue damage
of these therapies. Such a treatment would lead to an enhanced therapeutic index of radiation
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therapy and chemotherapy and improve quality of life and possibly increase survival for cancer
patients.

Nanomedicine is a field that studies the application of nanoscale compounds for medical
application in areas such as targeted drug therapy, implantable materials, biosensors, and
molecular imaging. There are currently over 200 nanomedicine products that are approved for
clinical use or in clinical trials.3 The most common type of nanomedicine is nanoparticles, which
have unique physiochemical and biological properties for many biomedical applications,
including cancer. One such nanoparticle is the cerium oxide nanoparticle (CONP). Research on
CONPs has demonstrated their radioprotective qualities for protection of normal tissue and
prevention of side effects during radiation therapy.4–9 This research has also shown in vitro that
their protective effect on cancerous tissue is minimal. While the mechanisms of this discrepancy
in protection are not yet completely understood, it may have to do with the different
microenvironment of tumor tissue compared to normal tissue. Prominent features of the TME
include changes to the extracellular matrix, a unique immune cell makeup, abnormal leaky
vasculature, increased interstitial pressure, and uneven blood flow.10,11 These factors contribute
to tumor hypoxia and acidic pH, which can affect drug uptake, metabolism, and mechanisms.12

Many developments in nanomedicine have also incorporated the use of molecular imaging, using
the nanomedicines as imaging agents, such as iron oxide nanoparticles as MRI contrast agents,
quantum dots in fluorescence imaging, and incorporation of radionuclides into nanoparticles for
SPECT/PET imaging. Molecular imaging is an integral part of diagnosing cancer patients and
planning and following response to therapy. Several imaging modalities are commonly used in
cancer patients, including MRI, PET, and CT. MRI images can better distinguish soft tissue
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structures, and can therefore better identify the boundaries of tumors. CT images are commonly
used as guides for biopsy and radiation therapy. PET imaging, specifically using [18F]FDG, can
best identify small tumor metastasis and tumor response to therapy. Research in molecular
imaging continues to improve the application of these imaging modalities in cancer, and clinical
translation of new imaging modalities, such as photoacoustic imaging, will make possible a
promising future of earlier detection and improved therapy for cancer patients.

2.2.

Radiation Therapy

Fifty percent of cancer patients currently undergo some form of radiation treatment during the
course of their disease. Several types of radiation treatments are available to patients. There are
three broad categories of treatment: brachytherapy, systemic radioisotope therapy, and, most
commonly, external beam. All of the methods have the same goal, to deliver a high dose of
radiation to cancerous tissue with the intent to kill cancerous cells, while best preventing dose to
surrounding normal tissue and associated side effects. Despite advances in radiation therapy
techniques, significant radiation dose to normal tissues remains unavoidable.

2.2.1. Brachytherapy and Systemic Radioisotope Therapy
Brachytherapy utilizes sealed radioactive sources which can be placed in close proximity to
tumors. The sources deposit a high dose to tumor while sparing surrounding normal tissue due to
rapid falloff of dose. The methods of implantation can be interstitial, placing the source directly
inside the target tissue, intracavity, mostly for uterine, cervical, or vaginal cancer, or external
applicators for surface treatment. Typical radioactive sources used in brachytherapy, listed in
Table 1, come in sealed containers to prevent leakage of activity. The sources can used for
permanent interstitial placement or for low dose rate (LDR) or high dose rate (HDR) temporary
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placement. Permanent placement involves isotopes with a short half-life and is used for slow
growing tumors, such as prostate, due to the slow dose deposition, which is less effective in
rapidly growing tumors.13 Iodine-125 is the most common permanently placed source, but GoldRadionuclide

Half
Life

Photon
Energy
(MeV)

Half-Value
Layer (mm
Lead)

Exposure
Rate Constant
(Γδ)a

Clinical
Application

Sealed Sources
Cesium-137
Cobalt-60
Iodine-125

30 yr
5.26 yr
60.2 d

0.662
1.17, 1.33
0.028 avg

5.5
11.0
0.025

3.26
13.07
1.46

Iridium-192

74.2 d

0.38 avg

2.5

4.69

Gold-198

2.7 d

0.412

2.5

2.38

Palladium-103

17 d

0.021 avg

0.008

1.48

Radium-226

1600
yr

0.83 avg

12.0

8.25b

LDR intracavitary
HDR intracavitary
Permanent
interstitial
LDR temporary
interstitial;
intracavitary; HDR
interstitial and
intracavitary
Permanent
interstitial
Permanent
interstitial
LDR intracavitary
and interstitial

-

-

Thyroid cancer

-

-

Ovarian cancer
seeding; peritoneal
surface; chronic
leukemia
Diffuse bone
metastases
Diffuse bone
metastases
Diffuse bone
metastases

Unsealed Sources
8.06 d
Iodine-131
Phosphorous-32

14.3 d

0.61 (βmax)
0.364 (γ)
1.71 (βmax)

Radium-223

11.4 d

5.78 (αavg)

-

-

Samarium-153

46.3 h

-

-

Strontium-89

51 d

0.81 (βmax)
0.103 (γ)
1.4 (βmax)

-

-

Table 1: Characteristics of radionuclides used in brachytherapy and their clinical applications. Lower energy
isotopes with short half-lives, such as 125I, 198Au, and 103Pd are used for permanent implantation, while higher energy
and longer half-life isotopes, including 137Cs, 60Co, 192Ir, and 226Rd are used for LDR and HDR temporary interstitial
and intracavitary placement. Unsealed sources can be given orally (131I), intraperitoneally (32P), or intravenously
(223Rd, 153Sa, or 89St).
a
Unfiltered, units Rcm2/mCi-h
b
Filtered by 0.5mm Pt, units Rcm2/mg-h
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198 or Palladium-103 may also be used. LDR sources, defined as rates between 0.4 and 0.8
Gy/hr, and HDR, rates greater than 12 Gy/h, are used in both intracavitary and interstitial
placement. The most common intracavitary placement is uterine/cervical, usually with a tandem
and ovoid device, seen in Figure 2, with isotopes such as Cesium-137 (LDR) or Iridium-192
(HDR).14 Interstitial brachytherapy usually requires surgical placement of sources with needles
or catheterization for afterloading the sources. Radium-226 was the most commonly used source,
but has since been replaced because of concerns of leaking. Iridium-192 is now commonly used,
which has a small source size and low photon energy for easier shielding. If catheters are placed
in the patient, a computer controlled afterloader can be used to automatically place and remove
radioactive seeds in the patient therefore minimizing dose to personnel.

Figure 2: Example of tandem and ovoid device implanted in a patient’s vagina/uterus for brachytherapy of uterine
or cervical cancer. The tandem (protruding tube in center), containing radioactive brachytherapy seeds, provides a
dose to the uterus and the ovoids (oval shapes at base of tandem), which also contain radioactive seeds, give dose to
the cervix. © Cancer Research UK / Wikimedia Commons / CC BY-SA 4.0.15
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Systemic radiation therapy is used by intravenous, intraperitoneal, or oral administration of
radioactivity, with a few example agents in Table 1. The agents must be taken up with high
specificity by the target organ to prevent damage to systemic tissues. One example is Iodine-131,
which is administered orally as NaI and localizes almost exclusively to the thyroid to treat
thyroid cancer. Phosphrous-32 can be used as an intraperitoneal injection as a chromic phosphate
colloid to deliver dose to the peritoneal surface. This therapy is used in conjunction with
brachytherapy for uterine cancer.16 Samarium-153 and Strontium-89 can be used to palliatively
treat diffuse bone metastases as these isotopes are taken up preferentially by bone, samarium
when chelated to ethylenediamine tetra(methylene phosphonic acid) (EDTMP) and strontium as
a substitute for calcium.17 Similarly, radium-223 is used to treat bone metastases with curative
intent and, as an alpha emitter, has high dose deposition at low range (<100 μm), decreasing dose
to surrounding tissues.18

2.2.2. External Beam Radiation
External beam radiation therapy is the most common type of radiation therapy. It can use
photons, electrons, protons, neutrons, or heavier ions as the energetic source of radiation. During
radiation therapy, patients are stationary and the source of radiation is pointed at the location of
the tumor. Radiation will deposit in tissue in a non-linear fashion that is dependent on radiation
type and energy, as seen in Figure 3. High energy electrons are deposited mostly near the
surface, with poor depth of penetration, and are only useful for superficial tumors less than 5cm
deep. High energy protons lose energy as they pass through matter at a rate which is inversely
proportional to their velocity, so as they slow down they deposit more energy, leading to what is
called a Bragg peak. Proton therapy utilizes this peak to create higher dose deposition to tumors
compared to surrounding tissue, but cost and few available facilities makes it less feasible as a
11

common treatment. High energy photon therapy in the tens of MeV have a peak in dose
deposition a few centimeters deep, which can be a benefit for skin sparing, that then tapers as
depth increases, allowing for dose deposition deeper in tissue. This type of radiation is the most
common form of external radiation therapy with applications for almost all tumor types.
The dose distribution profile of photon radiation therapy can be manipulated in several ways,
including beam flattening, wedges, shielding, and intensity modulation. Beam flattening ensures
that the same dose is deposited across the radiation field by making the beam intensity uniform
across the field. Similarly, wedges can prevent increases in dose deposition when using more
than one beam angle by partially blocking the radiation for overlap areas that would otherwise
get an increased dose. Shielding is most commonly used in the form of multileaf collimators

Figure 3: Depth dose distribution for 4 MeV electrons (purple/dotted), 4 MeV X-rays (blue/solid), 20 MeV X-rays
(green/dash-dot), and 150 MeV protons (red/dashed). The deposition of dose depends on both the energy and type of
radiation, with electrons showing deposition only at the surface, X-rays (photons) with excellent depth of
penetration and surface sparing at high energies, and protons with gradual deposition until a high deposition at the
Bragg peak. © Username: Cepheiden / Wikimedia Commons / CC BY-SA 3.0 / GFDL.19
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(MLCs), “leaves” of highly attenuating material that can move independently to create dynamic
patterns that collimate the beam to conform to the contours of the tumor, as seen in Figure 4.
Intensity modulated radiation therapy (IMRT) utilizes MLCs and computer assisted treatment
planning to optimize dose to tumor with minimal dose to surrounding at risk tissues. This
involves using several different configurations or dynamic movement of the MLCs at several
beam locations. The result of these dose distribution manipulations is a dose distribution that is

Figure 4: Multileaf collimator, which, when attached to a beam accelerator, can block and contour the beam. Each
“leaf” can be programed to move independently to create a collimated window. Single windows can be used per
beam in conformal radiation therapy (CRT), or have different windows stacked at the same beam position or make
the leaves move dynamically while the beam is on in intensity modulated radiation therapy (IMRT). © Username:
Egg / Wikimedia Commons / CC BY-SA 2.5.20
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highly concentrated in the tumor with the minimal dose possible to surrounding normal tissue, as
seen in comparison of 3-D conformal radiation therapy (3D-CRT) to IMRT in Figure 5.21 While
reduction dose deposition to normal tissue has continued to improve, radiation damage to normal
tissues surrounding tumors continues to be an issue.

Figure 5: A comparison of 3D conformal radiation therapy (3D-CRT), left, and intensity modulated radiation
therapy (IMRT), right. While both techniques use the same beam positions, the modification of the beams by
multileaf collimators in IMRT allows for a radiation dose that conforms to the shape of the tumor and better spares
surrounding structures from radiation damage. © International Journal of Cancer Therapy and Oncology (IJCTO) /
CC BY-SA 3.0.21

2.2.3. Radiobiology and Radiation Side Effects
The effects of radiation that lead to tissue damage occur at the subcellular level. The most
significant factor in radiation induced cellular damage is how the radiation affects DNA. There
are two mechanisms by which radiation can damage DNA, direct and indirect. Radiation can
directly damage DNA through breaking of the DNA backbone leading to single strand breaks, or
more damaging double strand breaks. Radiation can also cause the ionization of molecules in the
cell and produce free radicals, including hydrogen peroxide (H2O2) and superoxide (O2·-). These
free radicals can then go on to damage DNA base pairs. When DNA damage occurs and passes
the threshold where the cell cannot repair the damage, the cell signals to undergo apoptosis or
14

mitotic catastrophe and the cell dies.22 If enough cells undergo apoptosis, the tissue or organ
which they make up may have reduced function, leading to significant side effects.
Damage to normal tissues is the limiting factor for radiation therapy with proportionally
escalating dose to surrounding tissue as the dose is increased to tumor. The measurement of this
factor is called the therapeutic ratio or therapeutic index, the amount of expected tumor control to
expected side effects, as illustrated in the dose response relationship in Figure 6.23 The higher
the therapeutic index, the more likely treatment can be effective without significant side effects.
Radiation damage to tissue can cause side effects that present early or late. Acute side effects are
most common in radiosensitive organs. These are organs that have cells that are constantly
multiplying with stem cells replenishing tissue, such as in skin, the gastrointestinal tract, and
bone marrow. These organs show acute side effects that show up days to weeks after irradiation.
Skin irradiation causes reddening of the skin and hair loss. Gastrointestinal effects from radiation
include xerostomia (dry mouth), nausea and vomiting, and diarrhea. Irradiation of large sections
of bone marrow can cause pancytopenia and subsequent risk of infection. While these tissue are

Figure 6: Dose-response relationship demonstrating that an increase in probability of tumor control also leads to in
increased likelihood of complications from normal tissue damage. The dashed line represent the ideal point at which
tumor control is likely (>50%), but normal tissue damage is unlikely (<5%). The ratio of these values is the
therapeutic ratio or therapeutic index. Reprinted by permission from Macmillan Publishers Ltd: Nature Reviews
Cancer, Ref. 23, copyright 2009.
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some of the most radiosensitive, all organs can be damages by radiation, and can present late
effects. Some of the most important organs to protect due to more consequential side effects
include the heart, liver, and lungs. Late effects in these tissues include hepatitis in the liver,
pneumonitis and pulmonary fibrosis in the lungs, and fibrosis and cardiomyopathy in the heart.
Currently, the most common method to prevent the acute and late side effects from radiation
damage to normal tissues is using IMRT to avoid irradiating the tissue and decreasing the total
dose prescribed. There is currently only one drug approved for radiation protection, with many
more currently being researched.

2.2.4. Radioprotective Drugs
Research into radioprotective drugs began in 1948 with the discovery that high doses of cysteine,
a semi-essential amino acid with a sulfhydryl group, could protect mice if administered before
whole body irradiation. After administration of the drug at about 150mg/kg, mice required 1.8
times the radiation dose to produce the same mortality rate. The military implications of
radiation protection from atomic bomb fallout led to a program at Walter Reed Institute of
Research to develop similar drugs with less toxicity. Over 4000 compounds were tested, most
sharing the sulfhydryl group. It was found that the sulfhydryl group conferred radioprotection by
acting as a radical scavenger and assisted in DNA damage repair, but total mechanistic
understanding was not complete. Newer compounds decreased toxicity by covering the
sulfhydryl group with a phosphate group. Two compounds that came into common use from
those studied were WR-638 (cystaphos) and WR-2721 (amifostine).24 Other drugs capable of
reducing RT side effects have also been developed, such as thiols and nitroxides. However, their
own side effects can be self-limiting and their use is controversial as they lack mechanistic data
demonstrating if and how they completely prevent tumor radio-protection.25,26
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2.2.4.1. Amifostine
Amifostine is the only radioprotective drug approved by the U.S. Food and Drug Administration
(FDA) for use in radiation therapy. In a phase III clinical trial, it was shown to decrease
xerostomia (dry mouth) in patients undergoing radiation therapy for head and neck cancer, while
preserving antitumor treatment efficacy.27 The main drawback of amifostine is the high dose
required, about 400mg/kg, which led to significant side effects in these patients, with over 50%
having an incidence of nausea or vomiting and also having risks for hypocalcemia and
hypotension.28 Current use of the drug is still limited to head and neck cancer and concerns of
protection of tumor and loss of therapeutic efficacy, combined with its own side effect profile,
prevents its universal adoption in radiation therapy.

2.2.4.2. Characteristics of an Ideal Radioprotective Drug
As outlined in the introduction, an ideal radioprotective drug can be defined by four
characteristics.
1) Favorable biodistribution/pharmacokinetics
To prevent any excess toxicity, the drug must accumulate in normal tissue and have its
effect at low dose. It should not have tumor uptake that exceeds normal tissue uptake to
prevent any radioprotective effects on cancerous tissue. To prevent any long term effects,
it should clear from the body. Ideally the drug would be administered orally, which is the
simplest method of administration, but other options include intraperitoneal,
intramuscular, or intravenous administration.
2) Low toxicity
The drug should not have a side effect profile that may decrease the quality of life as
much as the expected side effects from radiation therapy. Some side effects can be
17

tolerable if they are outweighed by the expected decrease in side effects from radiation
therapy.
3) Minimal protection of cancerous tissue
The treatment should have minimal effect on the dose response for tumor, having little
effect on the curve for tumor control seen in Figure 6, and preventing the need for
significant dose escalation. If the drug protects cancerous tissue as much as it does
normal tissue, the dose of radiation would need to be increased to have the intended
cancer killing effects, which would also likely negate the radioprotective effects in
normal tissue. The effects on cancer tissue should be predictable to allow for consistent
adjustment of treatment planning to retain the efficacy of radiation therapy. It would also
be desirable for the agent to have a synergistic anti-tumor effect to potentially
compensate for any protection in the tumor.
4) Protection of normal tissue
The drug should prevent damage to normal tissue from radiation damage enough that
expected side effects are reduced or prevented entirely. The dose response curve for
normal tissue, seen in Figure 6, should shift significantly to the right, thereby increasing
the expected therapeutic index and allowing a higher dose for a better chance at tumor
control.
These would be the most important qualities for an ideal radioprotective drug, while more
pharmacodynamics information on dose response and mechanisms of action would further
support translation of the drug to the clinic.
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2.3.

Nanomedicine

Nanotechnology applications in medicine is an exciting field that has only existed for a few
decades. Clinical application of nanotechnology did not start until 1995 with FDA approval of
Doxil, a nanosize liposomal formulation of doxorubicin that enabled targeted delivery of the
chemotherapeutic drug with less toxicity.29 Though nanomedicine presents the possibility of
great leaps in medical therapy, it comes with many drawbacks including cost of development and
difficult standards for safety and efficacy due to the complex nature of many nanotherapies
compared to traditional molecular drugs. However, the potential benefits greatly outweigh the
drawbacks and nanomedicine continues to be at the forefront of research. Applications of
nanomedicine extend to almost all medical fields and include diagnostics, pharmaceuticals,
regenerative medicine, implants, nanosurgery, and nanorobotics.30–33

2.3.1. Nanoparticles
Nanoparticles (NPs) have combined unique physicochemical and biological properties for many
biomedical applications.34–38 NPs are made of various materials, including those made from bioorganic chemicals (e.g., phospholipids, lipids, dextran and chitosan), carbon-based materials (e.g.
carbon nanotubes) and inorganic NPs (e.g. those based on metals, metal oxides and metal
sulfides), also including semiconductor NPs (e.g. quantum dots).34,35,39–46 The design of NPs, in
terms of shape, size, surface charge, and material composition, will their physicochemical
properties, which in turn drives their in vivo biochemical interactions at the cellular and organ
levels. The unique ability to change these properties allows the control of NPs’ pharmacokinetic
properties, imaging properties, and toxicity.39,40,47–53 Compared to conventional drugs, this multifunctionality offers a novel approach to cancer therapy, giving them combined applications in
such areas as drug delivery, diagnostic imaging, and image-guided surgery.
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2.3.1.1. Intrinsic Radiolabeling of Nanoparticles
Deriving direct in vivo data on the behavior of NPs is essential to understanding overall
pharmacokinetics of various NP-chemical constructs. Incorporating an imaging signal in the NPconstruct enables in vivo imaging using various modalities, such as fluorescence and positron
emission tomography (PET). This can be accomplished either by covalently binding an imaging
molecule to the NP surface or by incorporating the imaging molecule into the NP core (intrinsic
labeling), as seen previously in Figure 1.52,54,55 Metal-based NPs are particularly attractive for
the latter approach as many elemental metals allow inherent radio-isotopic or fluorescent
detection. The Center for Molecular Imaging at Virginia Commonwealth University has
demonstrated the intrinsic labeling approach, using various radioisotopes, for three types of NPs:
cerium oxide NPs (CONPs) with Cerium-141, Indium-111, and Zinc-65, quantum dots with
Indium-111, and superparamagnetic iron oxide NPs (SPIONs) with Iron-59 and Manganese52.1,52,56

2.4.

Cerium Oxide Nanoparticles (CONPs)

Cerium oxide nanoparticles (CONPs) are unique among metal oxide nanoparticles for the
catalytic redox properties of their surface. Though the bulk material of CONPs is in the form
CeO2, with cerium in the Ce4+ oxidation state, oxygen vacancies on the surface of CONPs lead to
both Ce3+ and Ce4+ oxidation states being present. When reacting with oxidative species, these
oxidation states are able to auto-regenerate, as seen in Figure 7, allowing for catalyst-like radical
scavenging that mimics both superoxide dismutase (SOD) and catalase.8,43,57–60 These properties
have been extensively studied and have led to applications in industry and numerous pre-clinical
medical studies. Industrial applications include fuel cells, ultraviolet absorbance, oxygen sensing,
and automotive catalytic convertors.61–64
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Oxidative stress is ubiquitous as a common aspect in many clinical pathologies, and therefore
CONPs also have a broad potential for therapeutic applications. Within the last 15 years, CONPs
have been developed and studied for protection of tissues from oxidative and inflammatory
damage, which has been demonstrated in neuronal, ocular, and heart tissue.65–69 CONPs have
also demonstrated radioprotection of normal tissues, as seen in Figure 8, and lack of protection
of cancer cells in vitro, seen in Figure 9.4–9 Compared to conventional drugs, CONPs are a
unique radioprotective drug candidate with documented low toxicity.70 Other studies have shown
that redox-active CONPs exhibit cytotoxic and anti-invasive effects on several cancer cells and
are capable of sensitizing tumor cells to radiation, while protecting normal cells in the tumor
stroma.34,71,72 At pH 4.0 CONPs not only lose their ability to cycle back to the Ce4+ state, a
property that remains even after return to neutral pH, but also show significant oxidative
capabilities that could lead to cell damage.43,73 Tumor microenvironments provide a medium of
low pH that could selectivity reduce the radioprotective abilities of CONPs in tumor tissue.

Figure 7: Auto-regenerative properties of cerium oxide nanoparticles. In this proposed mechanism of CONPs’
reaction with hydroxyl radical [OH•], Ce3+ is converted to Ce4+, which then catalytically converts back to Ce3+.
Reprinted by permission from John Wiley & Sons Inc.: Small, Ref. 43, copyright 2008.
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Figure 8: CONPs improve toxicity after head and neck radiation. Radiation-induced dermatitis is reduced in mice
exposed to 30 Gray in 6 fractions to the head and neck region. Mice were given 15 nM or 15 μM uncoated CONPs
and showed quicker resolution of radiation dermatitis at 12 weeks in comparison to the control group that was only
irradiated. Reprinted by permission from Elsevier: Nanomedicine: Nanotechnology, Biology and Medicine, Ref. 6,
copyright 2012.

Figure 9: L3.6pl (pancreatic tumor) cells pre-treated with 10 μM CONPs for 24 hours followed by RT at 5 Gy show
a greater reduction in colony formation compared to radiation alone, indicating a possible radiosensitizing effect. .
Reprinted by permission from Elsevier: Nanomedicine: Nanotechnology, Biology and Medicine, Ref. 9, copyright
2013.
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2.5.

The Tumor Microenvironment

While many mutations in tumor cells may affect their uptake of drugs, the tumor
microenvironment (TME), with similar characteristics across many cancer types, also presents a
major hurdle for drug delivery to and therapy of cancer.12 An overview of the TME is seen in
Figure 10.74 A prominent feature of the TME is the abnormal leaky vasculature, allowing
passage of large molecules and causing increased interstitial pressure, and the uneven blood flow
leads to hypoxia and low pH.12,75,76 The immune cell makeup of the tumors is also drastically
different, with cell type changes that prevent immune destruction of the tumor.10 The
extracellular matrix also changes composition.11 All of these factors affect how drugs are
delivered to, taken up by, and chemically interact with the tumor cells, making cancer therapy
very unpredictable without precise understanding of the effects of the TME.

Figure 10: Overview of the tumor microenvironment (TME) and associated cells compared to normal tissue.
Prominent features of the TME include recruitment of mesenchymal stem cells (MSCs), activation of cancerassociated fibroblasts (CAFs), immune cell infiltration, leaky vasculature, increased interstitial pressure, abnormal
extracellular matrix (ECM), and areas of necrosis, hypoxia, and low pH. . Reprinted by permission from Macmillan
Publishers Ltd: Nature Reviews Immunology, Ref. 74, copyright 2015.
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2.5.1. pH and Hypoxia of the Tumor Microenvironment
The pH of the tumor microenvironment is lower than normal tissue pH 7.4, with an average of
7.0 with wide variance.77. Hypoxic regions are common to almost all solid tumors due to the
abnormal vasculature, with [O2] below 2%, compared to 7-10% in normal tissues, giving rise to
tumor radio-resistance.78 Drug therapies to normalize the pH and vasculature of the TME have
been studied, but the effects of altering the microenvironment are still not completely
understood.79,80

2.6.

Molecular Imaging

Molecular imaging modalities allow unique methods to non-invasively observe morphology or
biological processes in vivo. Modalities include positron emission tomography (PET), single
photon emission computed tomography (SPECT), optical fluorescence imaging, magnetic
resonance imaging (MRI), x-ray computed tomography (CT), ultrasound, and photoacoustic
imaging. Development of these imaging modalities has gone from focus on anatomical
information, to more detailed functional and molecular information, as outlined in Figure 11.
Each have their own advantages and disadvantages, as outlined in the two parts of Table 2. This
project utilized four modalities of molecular imaging: PET, CT, MRI, and fluorescence.

Figure 11: Development of biomedical imaging has progressed from a focus on anatomical information, to more
revealing and clinically relevant functional and molecular information.
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Imaging
technique
Positron
emission
tomography
(PET)
Single photon
emission
computed
tomography
(SPECT)

Detected
signal for
Spatial
image
resolution
generation

Depth

Temporal
resolution

Sensitivity

Quantitative
degree

high-energy
1-2 mm
γ rays

no limit

10 sec to
minutes

10−11–
10−12mole/L

+++

lowerenergy γ
rays

no limit

minutes

10−10–
10−11mole/L

++

<1 cm

not well
seconds to characterized,
minutes
likely 10−9–
10−12 mole/L

no limit

minutes to 10−3–
hours
10−5mole/L

no limit

minutes

1-2 mm

Optical
visible light
fluorescence or near2-3 mm
imaging
infrared
Magnetic
resonance radiowaves 25-100 μm
imaging (MRI)
Computed
tomography X-rays
50-200 μm
(CT)
highUltrasound frequency 50-500 μm
sound
highfrequency 50-500
Photoacoustic
sound (laser μm
excitation)

+ to ++

++

not well
characterized

++

several
seconds to not well
centimeters minutes
characterized

+

not well
several
seconds to characterized,
centimeters minutes
likely 10−9–
10−12 mole/L

++

Table 2: Characteristics of medical imaging modalities that have molecularly targeted imaging agents or nontargeted agents. Adapted from © Genes and Development / CC BY-NC 4.0.81
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Imaging
technique

Principal Use

metabolic,
Positron
reporter/gene
emission
expression,
tomography
receptor/ligand,
(PET)
enzyme targeting

Advantages
high sensitivity,
isotopes can
substitute naturally
occurring atoms,
highly quantitative

Optical
reporter/gene
fluorescence expression, cell
imaging
trafficking

many molecular
probes available,
can image multiple
probes at same
time, may be
adapted to clinical
imaging systems
high sensitivity,
quick, easy, low
cost

morphological
Magnetic
reporter/gene
resonance expression,
imaging (MRI) receptor/ligand if
many receptors

highest spatial
resolution,
combines
morphological and
functional imaging

Single photon
emission
reporter/gene
computed expression,
tomography receptor/ligand
(SPECT)

Computed
tomography morphological
(CT)

Ultrasound

Morphological,
blood flow

melanoma and
Photoacoustic lymph node
metastases

bone and tumor
imaging,
anatomical
imaging
real-time, low cost
spectral
information and
optical contrast
characteristics,
high resolution,
deeper into body
than fluorescence
imaging

Disadvantages
PET cyclotron or
generator needed,
relatively low
spatial resolution,
radiation to subject,
low specificity of
tracers (FDG)
relatively low
spatial resolution
because of
sensitivity,
collimation,
radiation

Clinical
Cost
Application
Yes

$$$$

Yes

relatively low
Yes, but
spatial resolution, limited
surface-weighted (surgical)
relatively low
Yes
sensitivity, long
scan and post
processing time,
mass quantity of
probe may be
needed
limited “molecular” Yes
applications,
limited soft tissue
resolution,
radiation
limited spatial
Yes
resolution, mostly
morphological
Yes, but
shielding by
limited (skin
strongly absorbing and shallow
objects
depth
newer technology examination)
with few current
probes

$$$

$–$$

$$$$

$$

$$

$$$$$

Table 2 (continued): Characteristics of medical imaging modalities that have molecularly targeted imaging agents
or non-targeted agents. Adapted from © Genes and Development / CC BY-NC 4.0.81
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2.6.1. Positron Emission Tomography (PET) Imaging
PET imaging is based on radioactive isotopes that can emit a positron during decay. Some
samples of isotopes used for PET imaging are found in Table 3. This positron is almost
immediately annihilated upon production when it comes in contact with an electron. The
annihilation produces two photons of 511 keV that are emitted along the line of response (LOR)
with nearly 180° separation, as seen in Figure 12.82,83 Once detected by photomultiplier tubes
surrounding the patient, a computer can calculate the origin of the photons by coincidence
detection and reconstruct into a three dimensional image. The intrinsic limitation of resolution
for PET imaging comes both from the distance the positron travels before it is annihilated, and
the slight deviation from 180° for the dual-photon release. For the positron, the mean free path
before annihilation is proportional to the maximum positron energy, so isotopes that produce less
energetic positrons will have better inherent resolution. Due to residual momentum of the
Nuclide Half-life
11

C

13

N

15

O

18

F

52

Mn
52
Fe
89

Zr

124

I

20.4
mins
9.96
mins
2.04
mins
109.8
mins
5.6 days
8.275 hrs

Decay
Modes
EC, β+

Maximum positron energy (MeV)
and yield (%)
0.961 (99.8%)

Production
14

N(p,α)11C

EC, β+

1.2 (99.8%)

16

O(p, α)13N

EC, β+

1.73 (99.9%)

15

N(p,n)15O
N(d,n)15O
18
O(p,n)18F
20
Ne(d, α)18F
52
Cr(p,n) 52Mn
52
Cr(3He,2n) 52Fe
52
Cr(α,3n) 52Fe
55
Mn(p,4n) 52Fe
89
Y(d,n)89Zr
89
Y(d,2n)89Zr
126
Te(p,3n)124I
14

EC, β+

0.634 (96.7%)

EC, β+
EC, β+

0.575 (29.6%)
0.804 (55.5%)

3.27 days

EC, β+

0.90 (22%)

4.18 days

EC, β+

2.138 (23.0%)

Table 3: The characteristics of various PET radionuclides.
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cannot be corrected for. The mechanical limit to resolution for PET comes from the detector size.
The resolution of commercial PET scanners, with wider bore and larger detectors, can be
reduced to around 5mm, while pre-clinical PET systems, usually with smaller bore and detectors,
can achieve a resolution as low as 1mm. Commonly, PET systems are combined with CT to
provide anatomical reference. Applications for PET imaging are focused on metabolic and
molecular information, with many compounds used to determine cell specific interactions in the
body, as seen in Figure 13.84

Figure 12: PET Scanner Schematic. An imaging agent with a positron emitting isotope is injected into a patient. A)
The positron will travel a short distance, proportional to its energy, before annihilating with an electron and emitting
two 511 keV photons. These photons, which are emitted at 180 ± 0.25°, travel to block detectors of the PET scanner
(B) which send data on the line of response (LOR) to a coincidence processing unit (C) and a computer for image
reconstruction (D). A) Jens Maus / Wikimedia Commons / Public Domain.82 B-D) Jens Maus / Wikimedia
Commons / Public Domain.83

28

Figure 13: Selected targets and corresponding nuclear imaging probes already established for nuclear molecular
imaging in the clinic (bold) or currently under assessment in clinical studies (italic). Reprinted from Clinical Cancer
Research, Ref. 84, copyright 2007, with permission from AACR.

2.6.1.1. [18F]-fluorodeoxyglucose
While many PET imaging compounds are approved for use in the clinic, the PET imaging agent
in most common clinical use is [18F]-fluorodeoxyglucose ([18F]-FDG). This molecule is
structurally similar to glucose, as seen in Figure 14, and is taken up by cells by the same

Figure 14: Chemical structure of [18F]-fluorodeoxyglucose ([18F]-FDG), left, compared to glucose, right. Due to the
similar chemical structure, the body takes up [18F]-FDG as it would glucose. PET imaging after injection of [18F]FDG allows for determination of metabolically active sites, such as tumors.
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transporters. Once [18F]-FDG enters the cell, it is phosphorylated to [18F]-FDG-6-phosphate,
which cannot leave the cell. Therefore, the radioactivity of 18F, detected by PET imaging, only
represents cells that take up the molecule. Uptake of [18F]-FDG mirrors metabolic activity, and is
therefore high in organs such as the heart and brain, and is particularly useful for detecting the
high metabolic activity of tumors. For [18F]-FDG imaging, the patient must fast for several hours
before administration of the activity to put the body in a glucose deficient state and increase
uptake of [18F]-FDG when administered.
Evaluation of [18F]-FDG imaging measures the standardized uptake value (SUV) of a region on
interest (ROI). This calculates the amount of [18F]-FDG taken up in a certain area relative to the
expected distribution based on the injected activity and body weight. The equation for SUV is:

𝑆𝑈𝑉 =

𝑐𝑖𝑚𝑔
𝐼𝐷′/𝐵𝑊

where cimg is the activity in the ROI, ID’ is the injected dose, decay corrected to the time of the
PET scan, and BW is the body weight. By correcting the activity of the injected dose for the
decay of 18F, the whole body will have an average SUV of 1. Areas of high metabolic activity
will have higher SUV values than surrounding tissue, with tumors and metastases having an
SUV that can range from 2 to 12.85,86

2.6.1.2. Zirconium-89
Zirconium-89 (89Zr) is an isotope that has increased in use in pre-clinical PET imaging studies.
The short half-life of 89Zr, 3.27 days, makes for an ideal candidate for clinical application in the
“happy medium” where longer studies can be performed but the patient dose will not be too
high. This is especially relevant for antibodies and macromolecules that have a similar biological
half-life in the blood. Compared to 124I, a commonly used PET radiotracer with a similar half-life
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and positron yield, 89Zr is superior due to its lower positron energy, allowing for higher
resolution imaging due to the shorter mean path of the positron before it is annihilated.87

2.6.2. Magnetic Resonance Imaging (MRI)
Magnetic resonance imaging (MRI) has become an important imaging modality in the clinic,
used primarily to examine anatomical structures with excellent soft tissue contrast when
compared to CT. MRI has many clinical applications, including cardiac imaging, neuroimaging,
musculoskeletal imaging, and angiography.88 The mechanism of MR imaging has to do with the
spin of an atom’s nucleus and its reaction to a magnetic field. For clinical MRIs, imaging is
exclusively done with hydrogen nuclei, which are abundantly present in the body in water
molecules. An MRI system is composed of a large magnet with a field strength of 0.2 to 7 Tesla.
The magnetic moment of hydrogen nuclei align themselves with this field when placed in the
bore of an MRI system, such that they spin at an angle, or precess, along this axis at a frequency
proportional to the magnetic field strength, as seen in Figure15.A and B.89 The frequency is
given by the Larmor equation:
f0 = γB0
where f0 is the precessional frequency, γ is the gyromagnetic ratio (42.57 MHz T-1 for hydrogen
nuclei), and B0 is the magnetic field strength. Higher field strength leads to higher signal to noise
ratio for images, but also results in inhomogeneities in the radiofrequency field and increased
specific absorption rate. When all the hydrogen nuclei are aligned in a field, there is a net
magnetic moment due to the slightly larger ratio of protons in the parallel, lower energy
orientation, than the anti-parallel, higher energy orientation (ratio = 1.000004). This magnetic
moment is on the order of 1 μT, which cannot be measured in the large magnetic field of the
MRI magnet. However, if this magnetic moment is shifted out of the plane of the MRI magnet’s
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field, it can be measured. To shift the magnetic moment to the transverse plane, an RF pulse at
the Larmor frequency is delivered, as seen in Figure 15.C. The magnetic moments in the
transverse and longitudinal planes are then measured continuously as the nuclei return to
equilibrium along the B0 field. The rate at which they return to equilibrium is measured as T1,
recovery of longitudinal magnetization, and T2, decay of transverse magnetization, as seen in
Figure 15.D and E. These two measurements are used to reconstruct images where different
tissues show different values for T1 and T2. T1 weighted images show better differentiation for
fatty tissues, while T2 weighted images are better for showing water content.
Contrast agents may be used to enhance contrast by affecting T1 and T2 specifically where they
are distributed in the body. Agents such as gadolinium and iron oxide nanoparticles are
paramagnetic and cause magnetization transfer to local bound hydrogen nuclei, reducing the T1

Figure 15: The precession, excitation, and relaxation of spins in MRI. A) Protons precess in a magnetic field. B)
The protons align in the magnetic field of the MRI, B0, creating a magnetic moment along the z-axis or longitudinal
plane. C) An excitation RF pulse, B1, is applied and the magnetic moment shifts to the y-axis, or transverse plane.
D) After the RF pulse, the magnetic moment shifts back to the longitudinal plane. The parameter T1 measures the
longitudinal magnetization and the parameter T2 measures the transverse magnetization. E) T1 is measured as the
time it takes for the magnetic moment to reach 63% of its initial intensity in the longitudinal plane. T2* is the time it
takes for signal in the transverse plane to decrease due mainly to inhomogeneities in the field. T2 is measured by
repeat RF pulses and measurement of maximum TE, echo time, signal. Reproduced from Postgraduate Medical
Journal, Ref. 89, copyright 2013 with permission from BMJ Publishing Group Ltd.
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to show as brighter areas or reducing T2 values to cause darker areas to appear where they are
concentrated, as seen in Figure 16.56

Figure 16: MRI phantom image for super paramagnetic iron oxide nanoparticles (SPIONs) with increasing
concentrations of Fe. Water, vial #0, is compared to vials containing SPIONs at increasing concentration of Fe from
#1 – 0.51 mg/L to #10 – 69.3 mg/L. This T2 weighted image shows decrease in signal at increasing concentrations
of SPIONs, demonstrating its ability to decrease T2 time. © American Journal of Nuclear Medicine and Molecular
Imaging, Creative Commons Attribution Noncommercial License.56

2.6.2.1. Chemical Exchange Saturation Transfer (CEST) MR
Imaging and pH Mapping
Chemical exchange saturation transfer (CEST) MR imaging is an MRI contrast imaging method
by which endogenous or exogenous compounds containing exchangeable protons or molecules
are selectively saturated and, after transfer of saturation, detected indirectly through
enhancement of water signal, as seen in Figure 17.90 Quantification of this signal is translated
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into maps that can be overlaid onto background MRI. CEST agents are beneficial compared to
typical contrast agents due to their ability to be turned on and off, allowing unaltered images to
be captured at the same time, they can be sensitive to environmental parameters such as
temperature, metabolite concentration, or pH, allowing quantitative measurement, and can be
administered as a cocktail for multiplex imaging, probing several targets. Applications for CEST
imaging include metabolite detection, imaging of mobile proteins or peptides in tissues, metal

Figure 17: Principles of chemical exchange saturation transfer (CEST) MR imaging. A,B) An endogenous or
exogenous agent with exchangeable protons are saturated at their resonance frequency, here 8.25 ppm, which is
visible initially (S0, B, left) until they are exchanged with water molecules after a period, t sat, decreasing the water
signal at 4.75 ppm (Ssat, B, right). C) Normalized water saturation (Ssat/S0) generates a Z- or CEST spectrum where
the direct saturation water peak is assigned 0 ppm. D) Magnetization Transfer Ratio (MTR) asymmetry analysis of
the Z-spectrum removes the direct saturation peak. Reprinted by permission from John Wiley & Sons Inc.: Magnetic
Resonance in Medicine, Ref. 90, copyright 2011.
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ion detection, liposome labeling, nanoparticle/polymer labeling, protein binding, RNA and
DNA-protein binding, temperature imaging, detection of enzyme activity, CEST reporter genes,
and pH imaging.91
Though many CEST methods have only been used for in vitro imaging, pH imaging has shown
promise for in vivo determination of acidic and basic regions and shows great promise for
clinical application. Although endogenous agents for CEST are ideal, pH CEST imaging uses
established CT contrast agents so clinical translation becomes much easier. These CT contrast
agents are iodine based, but contain amide protons for exchange with water, such as iopromide,
iobitridol, and iopamidol (trade names Ultravist, Xenetix, and Isovue, respectively). pH imaging
with these contrast agents is based on the pH dependent saturation transfer of several amide
protons within the contrast agent which can be expressed as a ratio that relates to the pH, as seen
in Figure 18.92 Measurement of the ratio of the saturation transfer of these protons allows for
concentration independent measurement of pH, as seen in Figure 19.93 In vivo imaging of mice
after intravenous injection of iopamidol has been used to determine pH in tumors and kidneys, as

Figure 18: pH responsive amide proton peaks in iopamidol and ratiometric measurement of pH. a) Iopamidol has
two amide protons with different chemical exchange saturation based on pH at 5.6 ppm and 4.2 ppm, seen in the Zspectrum of solutions ranging in pH from 6.33 to 6.96. b) Based on the known pH of solutions with iopamidol, a
correlation and equation can be created for the ratiometric determination of pH using the MTR spectrum from the
two peaks. Reprinted by permission from John Wiley & Sons Inc.: Magnetic Resonance in Imaging, Ref. 92,
copyright 2013.
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seen in Figure 20.94 Iopamidol has also been tested in a human volunteer using a clinical 3T MR
scanner to determine the pH of urine in the bladder, compared to pH of a urine sample, with
good correlation.95

Figure 19: Demonstration of concentration independent response of iobitridol as pH contrast agent. a) Iobitridolcontaining phantoms at different concentrations (10–50 mM) and pH values (6.6 and 7.2). MRI-CEST pH maps
show RF irradiation powers of 1.5/6 μT (b) and of 3/6 μT (c). Mean pH values calculated for several concentrations
upon ratioing 1.5/6 μT (d) and of 3/6 μT (e) demonstrating concentration independent pH measurements. ©
American Chemical Society, ACS AuthorChoice License.93

Figure 20: Saturation transfer maps of iopamidol in the kidneys, with ratiometric pH map. Saturation transfer maps
were created for amide proton peaks at 4.2 ppm (a) and 5.5 ppm (b). After applying the equation for ratiometric pH
dependence, a pH map is created showing slight acidity in the kidneys (c). Reprinted by permission from John
Wiley & Sons Inc.: Magnetic Resonance in Imaging, Ref. 94, copyright 2010.
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2.7.

Fluorescence Imaging and SNARF pH Indicators

Fluorescence imaging is based on the emission of light from a substance that has absorbed light
or other electromagnetic radiation, as seen in Figure 21A.96 The emitted light is always of lower
energy and higher wavelength than the absorbed light, seen in Figure 21B.97
Seminaphtharhodafluor (SNARF) compounds are a class of fluorescent molecules that have pH
sensitive fluorescent emission, as seen in Figure 22.98 These compounds can be made with
carboxylic acid, which makes them cell impermeable for determining external pH, or with
acetate ester, which causes cell uptake and can determine intracellular pH. Using a multispectral
fluorescence imaging system, images of cells or tissue treated with SNARF can be analyzed to
determine the pH based on the shift in fluorescent peaks.

Figure 21: Fluorescence of compounds is due to excitation and emission by electrons in the compound. A)
Electrons in the compound are excited from ground state (1) to an excited state (2) by in incident photon (blue), and
when they return to ground state (3) they lose energy in the form of light at an energy slightly below the incident
photon at a longer wavelength (red). B) Fluorescence spectrum demonstrating wavelengths absorbed (dashed) and
emitted (solid) by a fluorescent compound, fluorescein. A) Username: Mythealias / Wikimedia Commons / Public
Domain.96 B) © Username: Zadelrob / Wikimedia Commons / CC BY-SA 3.0.97
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Figure 22: pH dependent fluorescence emission by SNARF-1. SNARF-1, when excited at 534 nm, shows a shift in
fluorescent peak from 580 nm to 640 nm as its pH is increased from 6.0 to 9.0. Reprinted by permission from
Elsevier: Analytical Biochemistry, Ref. 98, copyright 1991.
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3. Chapter 3 - Approach and Methods

3.1.

Approaches to Gaps in Current Research on CONPs

Based on the current literature, this work aims to fill in some significant gaps in research on
cerium oxide nanoparticles that will hopefully advance their application towards the clinic as a
radioprotective drug. The first area to be studies is the biodistribution of CONPs once injected
into the body. This will be addressed through the synthesis of radiolabeled CONPs which can be
used for PET imaging and ex vivo biodistribution. Small molecule and polymer coatings on the
CONPs will also be studied to determine if altering CONPs’ size and surface charge affects their
biodistribution. With the new synthesis of coated CONPs, it will be determined if they retain the
same antioxidant properties as uncoated CONPs. Their toxicity in vitro will also be examined.
To determine their efficacy, the coated and uncoated CONPs will be tested for their
radioprotective properties in both tumor (in vitro and in vivo) and normal tissues (in vivo). Their
protection of normal tissue will be compared to the clinically available drug amifostine to
compare efficacy. Finally, the mechanism of action of changes in radioprotection in normal and
tumor tissue will be examined. The prevalent theory on CONPs lack of protection of tumor tissue
is that the acidic pH microenvironment of the tumor prevents radioprotection. This theory will be
tested in vitro and in vivo with a molecular imaging approach. By focusing on these gaps in the
research, this work presents novel contributions that may have an immediate impact on the
translation of CONPs into the clinic.
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3.2.

Synthesis of Non-Radiolabeled and 89Zr radiolabeled

CONPs
Synthesis of radiolabeled and non-radiolabeled CONPs is a single pot co-precipitation reaction.
Reactants include cerium(III) nitrate hexahydrate (Ce(NO3)3·6H2O), small molecule or polymer
for coating, and ammonium hydroxide (NH4OH). The small molecules and polymers used in
coating CONPs include citric acid, ethylenediaminetetraacetic acid (EDTA), dextran T10-amine
(DT10-NH2), dextran T10-polyethylene glycol (DT10-PEG), dextran T10-sulfobetaine (DT10SB) and poly(acrylic acid) (PAA). While all other polymer and small molecules in the synthesis
of CONPs were purchased and used without further modification, the DT10-NH2, DT10-PEG,
and DT10-SB polymers were synthesized de novo. 89Zr is produced by proton irradiation of a
natural yttrium target on a PET-Trace Cyclotron by IBA Molecular (Richmond, VA, USA). 89Zr
activity is radiochemically separated from the target using ion exchange chromatography to
produce 89Zr-oxalate in a solution of 1M oxalate. Due to the precipitation of cerium salts when
added to oxalate, the radioactive reaction yields of radiosynthesis of CONPs with 89Zr-Oxalate
were very low, less than 50% with significant precipitation visible in the reaction vial. To
prevent precipitation and increase radioactive yield, 89Zr-Oxalate was converted to 89ZrCl2 in 1M
HCl.

3.2.1. Functionalized Dextran T10 Synthesis
The dextran T10 based polymers used for coated CONP synthesis were synthesized de novo
using previously described methods.52 Briefly, 2-amino-ethyl-sulfobetaine (2-amino-ethyl-SB)
and amino-polyethylene glycol-600 (amino-PEG-600) were synthesized as precursors for
synthesis of dextran T10-sulfobetaine and dextran T10-polyethylene glycol, respectively. N,N-
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dimethylethylenediamine was purchased and used unaltered for synthesis of dextran T10-NH2.
Dextran T10 (1.0 g) was dissolved in DMSO (10 mL) with gentle heating and then cooled to
room temperature. N,N-Diisopropylethylamine (DIPEA, 0.64 mL) and di(Nsuccinimidyl)carbonate (DSC, 0.48g/0.96g/1.44g) in dimethyl sulfoxide/dimethylformamide
(DMSO/DMF, 2mL/2 mL) were added dropwise to the resultant solution with stirring to activate
the hydroxyl groups. The reaction mixture was left for 3 hours at room temperature and a
corresponding amount of amino derivatives (2-amino-ethyl-SB, amino-PEG-600, or N,Ndimethylethylenediamine) dissolved in DMSO or DMF or H2O (1.5 mL) was added to the
reaction mixture swiftly. The reaction was kept overnight at room temperature while stirring.
Functionalized DT10 (DT10-SB, DT10-PEG or DT10-NH2) was dialyzed against DI water
(dialysis cassette, molecular weight cut off: 2000 Da) and then dried under vacuum. The
functional degree could be tuned to 10%, 20% or 30%. DT10-SB-20%, DT10-PEG-20% and
DT10-NH2-10% were used for the synthesis of coated CONPs.

3.2.2. Preparation of 89ZrCl2
89

Zr-Oxalate in 1M oxalate was converted to 89ZrCl2 in 1M HCl using previously described

methods.99 Briefly, a Waters Sep-pak Light QMA strong anion exchange cartridge was prewashed with 6mL acetonitrile, 10mL 0.9% saline, and 10mL nanopure water. The 89Zr-Oxalate
was loaded onto the column and then rinsed with 40mL nanopure water. The 89Zr activity is
retained (>99%) in the column and oxalate is washed out by the water (<0.2% retained). The
89

Zr is eluted by 1mL 1M HCl and fractions are collected, with the highest activity fractions

combined (>90%) and used for subsequent reactions.
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3.2.3. Synthesis Scheme
An outline of the synthesis of coated and uncoated CONPs, with incorporation of 89Zr is seen in
Figure 23. Before beginning synthesis of CONPs, all of the reactants were prepared in solution,
as detailed in Table 4. Using the ratios described in Table 4, the non-radiolabeled synthesis is
detailed below:
(1) Combine the cerium salt and small molecule/polymer for coating in a vial. If synthesizing
uncoated-CONP, only cerium salt is required
a. For citrate-CONP, a neutral solution is required to prevent the precipitation of
cerium salt in EDTA. Mix citric acid and EDTA first, and then add NaOH to
neutralize, testing that the pH is between 6-7 (approximate volume of NaOH
required to neutralize is given). Add cerium nitrate solution last.
(2) By adding water, bring the total volume of the solution to 1mg Ce(NO3)3·6H2O per 300
µL
(3) Fill a separate vial with NH4OH (2.8% NH3 in water, 10x dilution of concentrated 28%
NH3 stock) to the same volume as the cerium salt solution in step (2). Using a stir bar, stir
the solution at 400 rpm.
(4) To the NH4OH solution, add the cerium salt solution from step (2) in a bolus.
(5) Allow the reaction to react for ~20 hours at room temperature (overnight)
(6) Pass the solution through a 0.2µm filter to remove large particles, rinsing the vial and
filter with water to maximize yield
(7) Do not use 0.2µm filter for uncoated CONPs (will not pass through filter) Transfer the
solutions into a molecular weight cutoff (MWCO) centrifugal filter, diluting the solution
to the recommended maximum volume and spin at ~5000 rcf for 30 minutes at room
temperature to remove any unreacted reactants.
a. Use 3 kDa centrifuge filter for citrate/EDTA and PAA coatings
b. Use 30 kDa centrifuge filter for uncoated and DT10-NH2, DT10-PEG, and DT10SB coatings
(8) Repeat step (7) 3 times, disposing of the filtrate and diluting the CONP solution each
time to the recommended maximum volume
(9) Collect the CONPs directly from the MWCO filter and rinse several times to collect
entire sample
(10)
Bring the final collected solution to a standard volume
(11)
Prepare samples for ICP-OES as detailed later in Section 3.2.1.1
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Reactant

Concentration

Ce(NO3)3·6H2O
NH4OH

100 mg/mL
2.8% NH3 in
H2O
200 mg/mL
50 mg/mL
160 mg/mL
200 mg/mL
75 mg/mL
100 mg/mL
100 mg/mL
Variable

Citric Acida
EDTAa
NaOHa
DT10-NH2b
DT10-PEGc
DT10-SBd
PAAe
89ZrCl f
2

Mass
Ratio
1
-

Volume
Ratio
1
15

Mass
Example
4 mg
-

Volume
example
40 µL
600 µL

2.7
0.3
1.6
2.5
2.5
2.5
2.5
-

1.35
0.60
1
1.25
3.33
2.5
2.5
-

10.8 mg
1.2 mg
6.4 mg
10 mg
10 mg
10 mg
10 mg
-

54 µL
24 µL
40 µL
50 µL
133.3 µL
100 µL
100 µL
-

Table 4: Reactants for non-radiolabled and radiolabeled CONP synthesis with several coatings. While
concentrations of starting reactants may vary, the mass ratio of the reactants should remain the same.
a
used only for citrate-CONP synthesis
b
used only for DT10-NH2-CONP synthesis
c
used only for DT10-PEG-CONP synthesis
d
used only for DT10-SB-CONP synthesis
f
used only for radiolabeled CONPs synthesis
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Figure 23: Synthesis scheme for uncoated and coated [89Zr]CONPs. For uncoated [89Zr]CONPs, cerium nitrate salt
and 89ZrCl2 solution was added to ammonium hydroxide to form a core of cerium oxide with stable incorporation of
89
Zr into the lattice. Similarly, coated [89Zr]CONPs were synthesized with the addition of polymers/small molecules
to the reaction mixture. The uncoated and coated [89Zr]CONPs (A-F) show the cerium oxide core (yellow spheres),
incorporating 89Zr (red dots) into the core. Also shown is the smaller size of the coated [ 89Zr]CONPs compared to
uncoated, but not to scale.
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To determine if zirconium could be efficiently incorporated into the core of CONPs, nonradioactive synthesis of stable zirconium labeled DT10-CONPs was performed as a proof of
concept. In these reactions, all conditions were kept the same except a solution of zirconyl
chloride octahydrate (ZrOCl·6H2O) was added to the cerium salt solution during step (1). In
three separate syntheses, the amount of zirconium added for incorporation was 0.5% (50 µg for
10 mg Ce), 1% (100 µg for 10 mg Ce), and 5% (500 µg for 10 mg Ce) of the mass of cerium in
the reaction. These concentrations were varied to reflect the trace amount of 89Zr, which is on the
order of 10 -100 ng.
The synthesis of any coated or uncoated CONPs can be altered to incorporate 89Zr into the core
of the nanoparticle. The radiosynthesis of CONPs is slightly altered from the synthesis above
with addition of 89ZrCl2 and dose calibrator measurements for radioactive yield, as detailed
below:
(1) Combine the cerium salt and small molecule for coating in a vial. If synthesizing
uncoated-CONP, only cerium salt is required
a. For citrate-CONP, a neutral solution is required to prevent the precipitation of
cerium salt in EDTA. Mix citric acid and EDTA first, and then add NaOH to
neutralize, testing that the pH is between 6-7 (approximate volume of NaOH
required to neutralize is given). Add cerium nitrate solution last.
(2) By adding water, bring the total volume of the solution to 1mg Ce(NO3)3·6H2O per 300
µL, minus the volume of 89ZrCl2 to be added in step 3
(3) Add a volume of 89ZrCl2 with the desired amount of radioactivity to the cerium salt
solution
(4) Fill a separate vial with NH4OH (2.8% NH3 in water, 10x dilution of concentrated 28%
NH3 stock) to the same total volume as the final volume of the cerium salt solution in step
(3). Using a stir bar, stir the solution at 400 rpm.
(5) To the NH4OH solution, add the cerium salt solution from step (3) in a bolus.
(6) Allow the reaction to react for ~20 hours at room temperature (overnight)
a. Measure and record the total activity of the reaction vial in a dose calibrator,
noting or setting the time of measurement for decay correction
(7) Pass the solution through a 0.2µm filter to remove large particles, rinsing the vial and
filter with water to maximize yield
a. Do not use 0.2µm filter for uncoated CONPs (will not pass through filter)
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b. Measure and record the activity remaining in the 0.2µm filter and empty original
reaction vial
(8) Transfer the solutions into a molecular weight cutoff (MWCO) centrifugal filter, diluting
the solution to the recommended maximum volume and spin at ~5000 rcf for 30 minutes
at room temperature to remove any unreacted reactants.
a. Use 3 kDa centrifuge filter for citrate/EDTA and PAA coatings
b. Use 30 kDa centrifuge filter for uncoated and DT10-NH2, DT10-PEG, and DT10SB coatings
c. Measure and record the total activity in the MWCO filter
(9) Repeat step (8) 3 times, disposing of the filtrate in radioactive waste and diluting the
CONP solution each time to the recommended maximum volume
(10)
Collect the CONPs directly from the MWCO filter and rinse several times to
collect entire sample
a. Measure and record the remaining activity in the MWCO filter
(11)
Bring the final collected solution to a standard volume
a. Measure and record the total activity collected in CONP solution
(12)
Prepare samples for ICP-OES as detailed later in Section 3.2.1.1
Typical addition of 89ZrCl2 was 0.1 to 1.0 mCi in 10 to 50 µL 1 M HCl.

3.2.4. Other CONP Coatings
Several other polymers and small molecules were tested for coating CONPs, including glucose,
cyclodextran, mannose, maltose, dextran T10, ascorbic acid, and dehydroascorbic acid. These
coatings were abandoned without further study in vitro or in vivo due to low reaction yields or
instability where significant aggregation was evident after a short period in solution.

3.3.

CONP Characterization

CONPs were characterized to determine concentration, size, and surface charge using
inductively couple plasma – optical emission spectrometry (ICP-OES), dynamic light scattering,
and zeta potential measurement, respectively. A dose calibrator was used during radiosynthesis
for radioactive yields.
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3.3.1. Concentration and Yield
To determine the concentration of CONPs in solution, inductively couple plasma – optical
emission spectrometry (ICP-OES) was used to measure the concentration of cerium in solution.
This value could also determine the reaction yield for CONPs. For radioactive yield, a dose
calibrator was used. ICP-OES was also used for testing of incorporation of non-radioactive
zirconium into CONPs.

3.3.1.1. Inductively Couple Plasma – Optical Emission
Spectrometry (ICP-OES) Measurement of Cerium
Inductively couple plasma – optical emission spectrometry (ICP-OES) is an instrument used to
detect trace metals in a sample. It uses an argon plasma torch to ionize metal atoms from a liquid
sample, usually in acid solution, which then produce photons at characteristic wavelengths that
can be detected by photomultiplier tubes. The amount of light given off from the sample is
proportional to the concentration of the metal in solution. This method can detect metals as low
as 2 ppb (2 ng/mL). The system used was a Vista-MPX CCD Simultaneous ICP-OES.
Preparation of cerium standards used 7% nitric acid as solution and ranged in concentration from

Log ICP-OES intensity
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0.25 to 50 ppm and showed linear response across that range, as seen in Figure 24. To saturate
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Figure 24: Inductively couple plasma – optical emission spectrometry (ICP-OES) of cerium shows good response
across a wide range of concentrations. Due to the wide range of response of ICP-OES and the range of concentration
of samples that can be used, a log-log plot was used to weigh each concentration equally, here showing
concentration ranging from 0.25 ppm (log value -0.6) to 50 ppm (log value 1.7).
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ionization and increase sensitivity, 0.01 M KCl was added to solution. CONP samples were
prepared by adding a volume of CONPs from the stock solution expected to create a
concentration within the range of the standards (1 – 100 μL) to 10mL 7% nitric acid solution.
The nitric acid dissolves the CONPs, producing free ions in solution for detection. A standard
curve was produced from the results of the standards, as seen in Figure X. The same methods of
sample preparation were used for determining non-radioactive zirconium incorporation into
CONPs by using zirconium standards from 20 to 400 ppb (R2 = 0.9964). AlCl3 (0.1 M) was along
with KCl (0.01 M) to increase sensitivity.

3.3.1.2. Radiochemical Yield Measurement
Radioactive reaction yields of 89Zr incorporation into CONPs was done using a Capintec CRC15 PET ionization chamber based dose calibrator. Using the steps outlined in the [89Zr]CONP
radiosynthesis detailed above, measurements were taken along the radiosynthesis to determine
the yield and if/when the radioactive yield decreased.

3.3.2. Size and Surface Charge
The coating of CONPs alters their size and surface charge. To determine these changes in
particle size and surface charge, a Zeta Sizer Nano Series ZEN3600 (Malvern, USA) was used.
Particle size is measured as the hydrodynamic size in water and is determined by dynamic light
scattering (DLS). DLS operates by diffraction of monochromatic light (635 nm) by particles in
solution. The diffraction pattern fluctuates in a manner that is due to the Brownian motion of the
particles, which can be correlated to the particle size. The diffraction patterns are analyzed by the
system correlator which can determine the size distribution of the particles. This method is able
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to determine particle size down to 1nm. Surface charge is measured as zeta potential. Zeta
potential is the electrokinetic potential of a particle compared to the dispersal media. It is
measured by electrophoretic mobility whereby an electric current is applied to the solution and
particle motion is measured. Concentrations used for hydrodynamic size and zeta potential
measurements were at least 0.1 mg/mL Ce.

3.4.

Autocatalytic Activity

To ensure the coating of CONPs and 89Zr incorporation into CONPs does not compromise their
unique redox properties, a previous method of measuring their redox reaction with H2O2 and
subsequent cycling back to original oxidative state was used.43,52 To determine the catalytic
activity of CONPs, their reaction with hydrogen peroxide (H2O2) was monitored using the
absorbance of CONPs, which changes depending of the oxidation state on the surface of the
nanoparticle, as seen in Figure 25. The immediate color change observed when H2O2 is added to
a solution of CONPs indicates the oxidation of Ce3+ to Ce4+ within the CONPs. This change in
absorption is most apparent at a wavelength of 420 nm, so this wavelength was used to measure

Figure 25: Solutions of [89Zr]CONPs before and after addition of H2O2. Solutions of [89Zr]CONP-Citrate (A,G),
[89Zr]CONP-PAA (B,H), [89Zr]CONP-DT10-NH2(C,I), [89Zr]CONP-DT10-PEG (D,J), Uncoated [89Zr]CONP (E,K),
and [89Zr]CONP-DT-SB (F,L) show very light yellow color before addition of H 2O2 (A-F) and immediate change to
dark yellow after addition (G-L). Uncoated [89Zr]CONP (E,K) shows milky solution due to large particle size and
aggregation while all coated CONPs (A-D, F-J, L) are transparent in solution.
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the change in absorption over time after the reaction with H2O2. The solutions gradually shift
back to a light yellow over the course of a few days, which indicates the auto-reduction of Ce4+
to Ce3+ within CONP. The experimental conditions for the autocatalytic reaction measurement
was 100 μL of 0.5 mg/mL of each type of CONPs or [89Zr]CONPs was added to a 96 well plate
and a multiwell plate reader (Beckman Coulter DTX880) was used to monitor the autocatalytic
activity by the absorbance at 420 nm (n=3). 20 μL of 7.5 mM H2O2 was added to each well to
oxidize the CONPs. The absorption was then monitored after addition of H2O2 over 5 days (t = 0,
1 hour, 1 day, 2 days, 3 days, 4 days, and 5 days). A repeat addition of 20 μL of 7.5 mM H2O2
was added to each well on day 6 to test the recycling of redox properties. Solutions of CONPs
without H2O2 were used as control to normalize reported percent absorbance.

3.5.

Cell Culture

Colorectal adenocarcinoma cell lines (COLO-205 and HCT-116) were maintained under
standard culture conditions (37o C and 5% CO2) in a humid environment. Cells were grown in
DMEM/High glucose medium supplemented with 10% fetal bovine serum. The cells were grown
to 70-80% confluency before using in the experiments.

3.6.

Cell Viability

Cell Titer-Glo Luminescent Cell Viability Assay kit (Promega) was used to evaluate the
cytotoxicity of CONPs on COLO-205 and HCT-116 cells. Briefly, 104 cells were plated in
opaque 96 well plates in triplicate for each concentration and treated with increasing
concentrations of citrate, DT10-NH2, DT10-PEG, DT10-SB, PAA coated and uncoated CONPs
and [89Zr]CONPs for 24 hrs. At the end of incubation period Cell Titer-Glo reagent was added to
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untreated and each treatment groups. The cell viability was assessed by measuring the
luminescence, detected by a multiwell plate reader (Beckman Coulter). The luminescent signal
generated being directly proportional to the ATP produced by metabolically active cells. The
luminescence detected in untreated cells was used as control (100% viability) to calculate
percent viability in treatment groups.

3.6.1. pH Effects on [89Zr]CONP Uptake In Vitro
For pH dependent uptake of [89Zr]CONPs, cells were incubated in DMEM/high glucose media
with 0.1 M MOPS buffer at pHs of 7.4, 7.0, and 6.6. To stabilize the media pH, 0.055 mol
MOPS buffer was added to 500mL of the media. The media was put on a heating/stir plate and
the temperature was kept at 37°C. A tube was placed in the media and room air (0.5% CO2) was
bubbled through the solution. After equilibrating with the room air, small volumes of 6 M NaOH
or 6 M HCl were added to the media until pH’s of 6.6, 7.0, or 7.4 were reached. Fetal bovine
serum (55 mL) was added after bubbling to prevent the solution from bubbling over. Final pH
values were ±0.01 pH units. Stability of pH was tested by incubating the media in an incubator at
37°C and 5% CO2. Media was stable at ±0.1 pH units for up to 3 days. The same methods for
cell uptake described above were used, with the cells pre-incubated in pH 6.6. 7.0, or 7.4 media.
COLO-205 cells grown in pH 6.6 media were not adherent, so the cell pellet was recovered from
the supernatant by spinning at 800 rpm and repeat washes with PBS and acid buffer wash were
done in a test tube with repeated spinning between each wash.

3.7.

Stability of [89Zr]CONPs

The most important concept in radiolabeling molecules for biodistribution studies is ensuring
that the radioactive signal represents the location of the molecule and can continue to do so in
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vivo over extended periods of time. During synthesis and collection, [89Zr]CONPs are purified
using a MWCO filter four times, removing any unreacted 89Zr, which passes through the MWCO
filter, from solution. This should indicate all radioactivity remaining is in the core of the
nanoparticle. To examine the stability of 89Zr incorporation into the core of [89Zr]CONPs,
several methods were used. A molecular weight cutoff (MWCO) method was developed to
determine stability of 89Zr in the core of [89Zr]CONPs after challenge with a strong chelating
agent, desferoxamine (DFO). Reversed phase high-performance liquid chromatography (RPHPLC) was also used for [89Zr]CONPs in water solution and for ex vivo plasma samples. The
inclusion of inline radioactive and UV detection system allows for simultaneous detection of 89Zr
radioactivity and CONP UV absorption.

3.7.1. Desferoxamine (DFO) Challenge
All of the coated and uncoated [89Zr]CONPs were incubated in 0.05 M desferoxamine (DFO) for
2 and 24 hours to test for chelation of free 89Zr. A separation test was performed based on size
by running samples through a 3,000 MWCO filter. This filter separates [89Zr]CONPs, which are
retained in the filter, from free 89Zr bound to DFO, which passes through the filter at >95%.
[89Zr]CONPs were run within two days of synthesis.

3.7.2. Radio- and UV-HPLC
Uncoated and citrate, PAA, DT10-NH2, DT10-SB and DT10-PEG coated [89Zr]CONPs in water
solution were analyzed by reversed phase high-performance liquid chromatography (RP-HPLC)
on a 8 x 300 mm, 200 Å Diol (YMC, Japan) size-exclusion column. Also analyzed were plasma
samples of C57BL/6 mice tail vein injected with [89Zr]CONPs taken 2 hours post-injection. 20
µL of sample solutions were injected into the HPLC with DI water as the mobile phase and a
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flow rate of 1 mL/min. Analysis of UV absorbance (254nm; model 2489, Waters) and
radioactivity (model B-FC-3300, Bio-scan) permits comparative analysis of CONP and 89Zr
signal, respectively.

3.8.

Spontaneous Colon Tumor Model

Colorectal cancer was produced in C57BL/6 mice (National Cancer Institute). Mice were given
an i.p. injection of the carcinogen azoxymethane (AOM) at 15mg/kg followed by three cycles of
colitis induction with dextran sodium sulfate (DSS) in drinking water (2% wt/vol) over 10
weeks, as previously described.100 Mice were monitored over the course of treatment for
diarrhea, blood in stool, and weight loss. Any mice that showed too much distress or lost greater
than 20% of their body weight were sacrificed. After tumor growth, some mice developed
prolapsed rectums, which were monitored closely and treated with antibacterial ointment. This
model is advantageous because of the fast time frame, 10+ weeks, for tumors to develop, and use
of spontaneous tumors better mimics human tumor development and response compared to
xenograft tumors in immunocompromised nude mice.

3.9.

Biodistribution

Animal experiments were performed according to the policies and guidelines of the Animal Care
and Use Committee (IACUC) at Virginia Commonwealth University. Adult female C57BL/6
mice (NCI) with colon tumors, induced as described above, were injected with the solution of
each variation of [89Zr]CONPs 0.37-11.1 MBq) in saline via the tail vein (i.v., n=3-6), oral
gavage (n=1), or intraperitoneal (i.p., n=1). Mice were given a dose used only for ex vivo
biodistribution were given a low dose of [89Zr]CONPs Mice were euthanized and blood samples
and other major organs were collected at 2 hours and 24 hours post injection. Radioactivity of
53

each sample was measured by gamma counter. The percentage of the injected dose per gram
(%ID/g) of tissues was calculated according the total injected dose, results of gamma counting
and organ weights.

3.9.1. Ex Vivo Biodistribution
Mice to be used only for ex vivo biodistribution were given a low dose of [89Zr]CONPs (5-25
μCi) and organs were excised and collected for gamma counting on a Perkin Elmer Wallac
Wizard 1470. The organs excised for counting are given below:

3.9.2. Whole Body Radioactivity
For determining excretion of CONPs, a large dose was given to C57BL/6 mice (89-128 μCi) and
the whole body activity was recorded over the course of 7 days using a dose calibrator.
Measurements were taken initially, and at 5 minutes, 15 minutes, 30 minutes, 1 hour, 2 hours, 4
hours, 8 hours, 1 day, 2 days, 3 days, 5 days, and 7 days. Body weights were measured initially
and at each measurement from 1 day on.

3.9.3. In Vivo PET/CT Imaging of [89Zr]CONPs
For dynamic and static PET/CT imaging, animals were anesthetized (2% isoflurane in oxygen)
for about 10 minutes before the animals were positioned in a commercial Multi-modality
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Preclinical System (Inveon, Siemens Healthcare, PA). For dynamic scans, PET data was
acquired for 65 continuous minutes under warm conditions. Two minutes after the start of the
image acquisition, the various [89Zr]CONPs (70 – 320 μCi) were injected via the tail vein
through a previously positioned catheter while the PET image acquisition was already
commenced (n=1). After 65 minutes of dynamic scan, a CT scan was also acquired for
anatomical reference. Static scans were performed at 2 hours and 24 hours after injection of
various [89Zr]CONPs (50 – 320 μCi) were injected via the tail vein, with follow-up CT scan. A
normalization scan and a calibration phantom of known volume and activity were acquired prior
to the studies and the PET images were processed using manufacturer recommended procedures.
Multiple frame dynamic sequences and ordered subsets expectation maximization three
dimensional - maximum a posteriori (OSEM3D-MAP) reconstructions were done using Inveon
Acquisition Workplace 1.5 (Siemens Healthcare, PA) and were used for image analysis in the
Inveon Research Workplace 4.1 (Siemens Healthcare, PA).

3.10.

Irradiation and Radiation Therapy

Two separate systems were used for irradiation of cell culture or mice. A Cesium-137 (137Cs)
irradiator was used for cell culture and whole body mouse irradiation, while a small animal
radiation research platform (SARRP) was used for stereotactic mouse irradiation.

3.10.1.

Cesium-137 Irradiation

A 137Cs source was used for irradiation of cell culture and whole body irradiation of mice. Cell
cultures were given a dose of 5 Gray, while mice were given a whole body dose of 10 Gray.
Mice were sacrificed immediately following whole body irradiation, so no side effects were
experienced.
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3.10.2.

Small Animal Radiation Research Platform (SARRP)

The small animal radiation research platform (SARRP) is a radiation system capable of
mimicking clinical conformal RT in animal models. The platform simulates doses, cell damage,
and side effects produced by clinical RT. The system has a dual source x-ray tube, allowing for
cone beam CT imaging and treatment plans that can be developed using 3D software. The
treatment plans can be based on pre-clinical imaging through multi-modality image registration
encompassing PET, SPECT, MRI, and other CT images. Treatment plans are developed on the
SARRP using custom Slicer 3D. The CT scan is transferred to the Slicer 3D software as a
DICOM image which contains attenuation information. Using this data, segmentation is
performed to determine the soft and hard tissue structures in the mouse, including lungs, fat,
tissue, and bone, as seen in Figure 26. This data is used to calculate the time of irradiation for
the dose prescribed. Several isocenters can be selected for the irradiation of tissue. Beam
placement can be done completely in three dimensions with the platform rotatable and the

Figure 26: Segmentation of SARRP CT. The SARRP system is capable of taking a CT scan of the mouse on the
platform for radiation treatment planning. To accurately compute dose and irradiation time, segmentation is
performed to tell the system the density of the tissue being irradiated, including lung, fat, tissue, and bone. Views are
coronal (top left), axial (bottom left), and sagittal (right).
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beam head able to rotate in a circle around the platform, as seem in Figure 27. The collimators
available range in size from 1 mm circle to 10 mm square for precision dose to specific areas.

Figure 27: Mouse and beam collimator in place for colon irradiation. Mice are anesthetized with ketamine/xylazine
and immobilized on the carbon fiber platform, which is able to rotate 360° and move up and down in the z-plane.
The beam collimator can move around the mouse 360°, shown here at a 45° angle. Collimators can range in size
from 1 mm circle to 10 mm square, seen here.

3.10.3.

Normal Colon, Colon Tumor, and Xenograft Irradiation

Based on mouse anatomy, which have a colon that travels along the midline, normal mice and
colon tumor bearing mice were irradiated along the midline from the rectum to 3 cm towards the
cranium to irradiate the entire colon. The beam profile was developed with 2 beam positions
used at each of 3 isocenters. The first isocenter was selected to cover the entire rectum and each
subsequent isocenter was placed exactly 10 mm cranially. The use of the 10 mm collimator
allows for placement of beams directly adjacent without overlap or gaps in dose, as seen in
Figure 28. Two beams were used at each beam location at 45° and -45° to prevent high surface
dose deposition and avoid attenuation of the beam by the spine. Xenograft tumor bearing mice

57

with tumors on their rear flanks were irradiated from a single beam position, as seen in Figure
29.

Figure 28: Treatment planning for mouse colon irradiation. Three isocenters are placed 10 mm apart for use of the
10 mm beam collimator. Beams are planned at 45° angles, outlined in purple, to prevent high skin dose and
attenuation by the spine. Dose is 10 Gy with even distribution across the whole colon, 3 cm from rectum to midbelly. Views are coronal (top left), axial (bottom left), and sagittal (right).

Figure 29: Treatment planning for mouse xenograft irradiation. A single isocenter was placed in the center of the
xenograft tumor and beam was placed a 0° above the tumor. Dose is 10 Gy with even distribution within the tumor
volume. Views are coronal (top left), axial (bottom left), and sagittal (right).
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3.10.1.

CONP and Sodium Bicarbonate Pre-treatment Before

Irradiation
The dose given for CONP treatment of mice for therapeutic dose was 1 mg/kg (cerium mass).
Based on highest uptake from biodistribution results, mice were given this dose 2 hours before
irradiation by tail vein injection in 200 μL saline. To normalize the pH of the tumor
microenvironment, treatment with sodium bicarbonate was chosen. Xenograft bearing mice in
the group for pH normalization were given 700 µL of 1 M sodium bicarbonate solution by oral
gavage. Based on the response of tumor pH in the literature, mice were given sodium
bicarbonate three hours before imaging or irradiation.101

3.11.

Evaluation of Response to Radiation

Evaluation of response to radiation was measured from in vitro, ex vivo, and in vivo samples. In
vitro measurement of pH response was done using clonogenic assays. Ex vivo samples of
xenograft tumors were also used for clonogenic plating. Ex vivo samples of normal colon were
stained for apoptosis using a TUNNEL assay. In vivo imaging was used to measure tumor
response. For spontaneous colon tumors, [18F]FDG PET imaging was used to determine tumor
metabolic activity. For xenograft tumors, MRI imaging was used to follow tumor growth and
regression following irradiation.

3.11.1.
Effects of pH on Radiation Response of CONP Treated
Cancer Cells
HCT-116 colon cancer cells were used to determine the effects of pH on radioprotection of
cancer cells by CONPs in vitro using clonogenic assay. HCT-116 cells were plated at 500 cells
per dish in 10 cm2 dishes. The dishes were separated into sets of controls, PAA-CONP treated
only, irradiation only, or PAA-CONP plus radiation and each set was incubated in media pH of
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7.4 or 7.0 (n=3). The PAA-CONP treated cells were incubated for 2 hours in media containing
15 μg/mL CONP by cerium mass until changing media back to normal. The media was also
changed in the other control/irradiation only dishes. For the PAA-CONP plus radiation group, at
the two hour time point the dish was irradiated and media was changed after. The irradiated
dishes received a 5 Gray dose from the 137Cs source. Dishes were left alone in the cell incubator
for 14 days for colony growth. After 14 days the dishes were removed, media was removed and
the colonies were stained with crystal violet (0.5%) for 20 minutes and the dishes were rinsed
and colonies counted.

3.11.2.
Clonogenic Assay of CONP and Irradiation Treatment of
Xenograft Tumors
Effects of CONPs on HCT-116 xenograft response to radiation was determined by clonogenic
plating of xenograft tumors. Athymic nude mice (NCI) were implanted subcutaneously with 2.5
million HCT-116 cells in matrigel in their rear flank. Mice were separated into groups of control,
PAA-CONP treated only, irradiation only, or PAA-CONP plus radiation (n=3). Mice were given
whole body radiation dose of 10 Gray from the 137Cs source. Immediately after irradiation,
tumors were excised, minced, and incubated in a solution of 0.25% trypsin and 0.002% DNase I
in FBS-free DMEM/high glucose media at 37°C for 20 minutes. After incubation, cells were
pelleted and counted and plated at 5000 per dish in 10 cm2 dishes. Dishes were left alone in the
cell incubator for 14 days for colony growth. After 14 days the dishes were removed, media was
removed and the colonies were stained with crystal violet (0.5%) for 20 minutes and the dishes
were rinsed and colonies counted.
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3.11.3.

In vivo PET/CT [18F]FDG Imaging of Spontaneous Colon

Tumors for Response to CONP and Radiation Treatment
To evaluate the effects of CONPs on tumor response to radiation, [18F]FDG PET imaging was
used before and after irradiation of spontaneous colon tumor bearing animals using the SARRP
system. Mice were separated into groups of control, PAA-CONP treated only, irradiation only,
citrate-CONP plus irradiation, DT10-PEG-CONP plus irradiation, PAA-CONP plus irradiation,
or uncoated CONP plus irradiation (n=3). The initial scan provided a baseline of metabolic
activity in the tumors. One day after [18F]FDG PET imaging, the mice’s colons were irradiated
with the SARRP system, as described in Section 3.10.3. Two weeks after irradiation, [18F]FDG
PET imaging was repeated to determine tumor response.
Analysis of [18F]FDG PET images was done in Inveon Research Workplace 4.1 (Siemens
Healthcare, PA). Regions of interest (ROIs) were created in the coronal plane outlining the colon
tumors, careful to avoid inclusion of the bladder due to high urine content of [18F]FDG, as seen
in Figure 30. Tumor volumes were determined using a threshold standardized uptake value

Figure 30: Evaluation of tumor volume from [18F]FDG PET imaging. Rough outline of tumor was done in all
coronal planes, careful to avoid the bladder due to high urine concentration of [18F]FDG, seen in the center image as
the blue outline. The tumor volume was calculated as any voxels with an SUV greater than 2.5, seen in the center
image as the yellow outline. Views are axial (left), coronal (center), and sagittal (right).
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(SUV) of 2.5, for all images, which corrects for the injected dose and body weight of the animal
and does not account for any surrounding [18F]FDG tissue uptake.

3.11.4.

Ex Vivo Normal Colon Tissue Analysis

Testing of the radioprotective effects of CONPs was chosen to be done in the colon because of
its high and acute radiosensitivity. The most radiosensitive part of the colon are the crypt stem
cells, which divide to produce the cells that migrate and become the colonic villi, as seen in
Figure 31. To examine colon response to irradiation and potential protection by CONP pretreatment, C57BL/6 mice were separated into groups of control, irradiation only, citrate-CONP
plus irradiation, DT10-PEG-CONP plus irradiation, PAA-CONP plus irradiation, uncoated
CONP plus irradiation (n=3). Amifostine pre-treated animals were also irradiated to compare
CONPs to an established radio-protective drug (n=3). CONP treatment and amifostine treatment
were given 2 hours before irradiation

Figure 31: Structure of colon villus and crypt cells. The stem cells (green) that divide into the progenitor cells and
produce the entire library of colon cells are the most susceptible to radiation damage. © Integrative Biology / CC
BY-SA 3.0 102
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To determine the response of the colon to radiation, measurement of apoptosis was chosen to
determine if it could be reduced after radiation treatment. According to the literature, apoptosis is
maximally evident in the colon at 4 hours post-irradiation.103 All mice were therefore sacrificed
at 4 hours after irradiation and their colons were excised and frozen in optimal cutting
temperature (OCT) compound as a “swiss roll,” as seen in Figure 32. A fluorescent terminal
deoxynucleotidyl transferase (TdT) deoxyuridine triphosphate (dUTP) nick end labeling
(TUNEL) assay (ApopTag® Fluorescein In Situ Apoptosis Detection Kit, EMD Millipore) was
used to quantify apoptosis. This assay works by detecting the DNA fragmentation that occurs
during the apoptosis process. Free 3’-OH termini, or “nick ends,” are detected by enzymatic
action of TdT and labeled with dUTPs. For the ApopTag assay, digoxigenin labeled dUTPs are
included and also label the DNA termini. The tissue is then incubated with an anti-digoxigenin
antibody conjugated to fluorescein. This fluorescent labeled antibody can be detected by
fluorescent microscopy.

Figure 32: “Swiss roll” of mouse colon. A mouse colon is cut longitudinally and rolled from the rectum forward
into a cylinder. Cutting along the base of the cylinder allows for staining and microscopy of the entire length of the
colon in a small area.
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In this experiment, colon cryosections were created at 6 μm on a cryostat (Leica) and placed on a
microscope slide, with at least 2 sections from each mouse colon. The sections were preserved at
-20°C until staining. The slides were stained using the Apoptag assay and counterstained with
nuclear staining 4’,6-diamidino-2-phenylindole (DAPI), which binds to the minor groove of
double stranded DNA, increasing its fluorescence 20-fold. DAPI was contained in the mounting
media (Vectashield) used during slide preparation. Nuclear staining allowed for quantification of
apoptosis based on total number of cells present.
Analysis of colon slides was done in ImageJ (NIH) by using a threshold quantification after
artifact removal, as seen in Figure 33 and Figure 34. Briefly, apoptosis staining was determined
by using the default threshold and sliding it uniformly by 15 units to display only cells that
showed apoptosis staining, as seen in Figure 33 D and H, and in detail in Figure 34D. Nuclear
staining was determined similarly, using the default threshold with no shifting necessary to

Figure 33: Nuclear and apoptosis staining and analysis of swiss rolls of control colon (A-D) and irradiated colon (EF). DAPI staining of control (A&B) and irradiated (E&F) colons allowed for background nuclear detection,
quantified using a threshold, seen in B&F. Apoptag staining of control (C&D) and irradiated (G&H) colons allowed
for quantification of cells that were apoptotic. As expected, irradiated colons showed significantly more apoptosis
than non-irradiated (H and D, respectively).
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display only nuclear stained cells, as seen in Figure 33 B and F, and in detail in Figure 34B.
After conversion to binary, ImageJ was used to analyze the area of stained cells. The ratio of
apoptosis staining to nuclear staining was used to determine the apoptotic index. It could be seen
in the apoptosis staining that the apoptosis in the colon was occurring in the crypt stem cells,
which is expected because they are very radiosensitive as highly proliferative cells, as seen in
Figure 34.

Figure 34: Detail of nuclear and apoptosis staining control colon (A&B) and irradiated colon (C&D). Thresholding
method allowed for removal of background signal, while only detecting cells stained for nucleus (B) or apoptosis
(D).

3.11.5.
MRI Imaging of Xenograft Tumors to Determine pH Effects
on CONPs’ Radioprotection of Tumor

To determine if the radiation protection of CONPs within tumors is affected by their pH, mice
were treated with sodium bicarbonate to normalize the pH of the tumor microenvironment. In the
experiment, mice were separated into groups of control, sodium bicarbonate plus irradiation,
PAA-CONP plus irradiation, and sodium bicarbonate and PAA-CONP plus irradiation.
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To evaluate if pH effects CONPs radioprotective ability in tumors, T2-weighted MRI scans were
taken before and 2 weeks after treatment of the xenograft bearing nude mice. Using ImageJ
(NIH) and a plugin software called VolumEst, the average tumor volume was determined to
compare response to therapy, as seen in Figure 35.

Figure 35: Volume estimation of xenograft tumors using ImageJ and VolumEst. DICOM image stacks from T2
weighted MR imaging of xenograft bearing mice before and two weeks after treatment. Tumors were outlined in
each slice of the images and the software calculated the tumor volume based on slice thickness.

3.12.

pH MRI Imaging

Using a protocol developed by Dr. Vimalan Vijayaragavan at the Center for Molecular Imaging,
VCU, xenograft bearing mice were imaged using a CEST protocol to develop pH maps of the
tumors. CEST MRI technique is widely used to calculate pH in vivo. In our case we used
iopamidol, a CT agent containing amide protons which is exchangeable with bulk water
molecule. Athymic nude mice (NCI) with HCT-116 xenograft tumors on their rear flank were
anesthetized (2% isoflurane in oxygen) for about 10 minutes before the animals were positioned
in a 7 T pre-clinical MRI scanner (Bruker). T2-weighted reference scans were performed before
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iopamidol, as clinical grade Isovue 300, was injected by catheter (200 μL, 122.4mg). The CEST
experimental parameters are as follows: A Rapid Acquisition with Relaxation Enhancement
(RARE) pulse sequence with a saturation module of a block pulse of 5 second duration, with 3
μT amplitude is used for saturation in the frequency offset range -10 ppm to +10 ppm in 0.3 ppm
increment. A slice thickness of 1.5 mm with 9 slices to cover the whole tumor was used. A
matrix size of 64×64 with an isotropic FOV of 35 mm with a rare factor of 64 was used. The
repetition time (RT) and echo time (TE) being 47 sec/4.75 ms. The pH was evaluated based on
ratiometric technique involving the signals at 4.3ppm and 5.5ppm using a Matlab program
developed by Dr. Vijayaragavan.

3.13.

Ex Vivo Validation of pH Imaging

Two methods were used for ex vivo validation of MRI pH imaging. Use of a micro pH electrode
probe with a needle tip (ORION® Needle Tip Micro Combination pH Electrode, Thermo
Scientific) allowed for direct measurement of pH in the tumor, but with little spatial accuracy. A
fluorescent dye with pH sensitive response was used, SNARF-5F 5-(and-6-)-carboxylic acid
(Thermo Fischer).

3.13.1.

Tumor pH Imaging Using SNARF-5 Fluorescence

A SNARF compound, as described in Section 2.7, was used for ex vivo measurement of tumor
pH. With a pKa value of ~7.2, SNARF-5F 5-(and-6-)-carboxylic acid was chosen as the best
candidate for evaluation of tumor pH before and after normalization with sodium bicarbonate
therapy. The carboxylic acid derivative was chosen to determine extracellular pH to compare
with the MRI pH mapping and pH needle probe measurements. Imaging was done in a
multispectral fluorescence imaging system (Maestro, CRi). Solutions of SNARF, 1 μM, in pH
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solutions ranging from 6.4 to 7.6, Figure 36, were imaged and showed significant shifts of
fluorescence peak when excited at 523 nm, as seen in Figure 37. Using the Maestro software,
images were unmixed based on the known pH of the solutions, producing an image showing the
different pH solutions as different colors. Xenograft bearing mice with and without sodium
bicarbonate pre-treatment were injected with SNARF-5F (0.25 μmol in 200 μL saline) and
sacrificed 15 minutes later. Tumors were excised and sliced before imaging.

Figure 36: Fluorescence emission shifting in SNARF-5F in different pH solutions. 1 μM solutions of SNARF-5F
buffered to pHs between 6.4 and 7.6 show significant shift in fluorescent peaks, increasing at 560 nm and decreasing
at 630 nm as solutions become more acidic.

Figure 37: Solutions of SNARF-5F after unmixing of fluorescence. Using Maestro software’s spectral unmixing,
solutions of SNARF-5F with concentration ranging from 6.4 to 7.6 show up in their assigned color. This indicates
SNARF-5F’s excellent response in the pH range expected in tumors versus normal tissue.
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3.14.

Statistical Methods

Statistical analysis was performed using Student's t-test. A P value of <0.05 was considered
statistically significant. Microsoft Excel software was used for all statistical analyses.
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4. Chapter 4 – Results

4.1.

CONP and [89Zr ]CONP Reaction Yield and

Physicochemical Properties
The synthetic and radiochemical yields as well as physicochemical properties of the various
CONPs and [89Zr ]CONPs are presented in Table 5 for review in this section.

CONP
Coating

CONP
Yield
(%)

[89Zr ]CONP
Yield
(%)

CONP
Hydrodynamic
size
(nm ± SD)

[89Zr ]CONP
CONP
Hydrodynamic
Zeta
size
potential
(nm ± SD) (mV ± SD)

[89Zr ]CONP
Zeta potential
(mV ± SD)

Citrate/EDTA

89.2%

87.8%

3.1 ± 0.5

3.1 ± 0.7 -34.7 ± 0.9

-33.0 ± 5.1

DT10-NH2

99+%

93.0%

6.3 ± 1.8

6.2 ± 1.6

17.3 ± 5.0

18.5 ± 5.7

DT10-PEG

99+%

94.6%

9.3 ± 2.7

9.4 ± 2.4

6.6 ± 5.0

7.3 ± 4.8

DT10-SB

99+%

94.9%

14.3 ± 4.6

14.2 ± 4.4

-8.4 ± 0.6

-13.7 ± 0.6

PAA

96.5%

97.7%

3.9 ± 0.9

3.8 ± 0.7

-5.4 ± 1.3

-5.3 ± 1.2

Uncoated

78.5%

80.9%

156.8 ± 35.4

163.3 ± 40.6 -23.2 ± 2.8
(90%)
1128 ± 342 (10%)

-23.8 ± 10.0

Table 5: Reaction yields, hydrodynamic size, and zeta potential of the various CONPs and [89Zr ]CONPs.

4.1.1. Reaction yield of Non-Radioactive CONPs
Synthesis of uncoated CONPs and CONPs with different coatings, as described in Section 3.1.3,
resulted in different yields, sizes, and surface charges. The reaction yields of coated CONPs were
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all above 89% by measure of cerium content by ICP-OES. While the reaction yields of the
DT10-based coated CONPs were all nearly 100%, the lower reaction yields of citrate and PAA
coated CONPs were due to some of the nanoparticles passing through the MWCO filter due to
smaller size of these nanoparticles, as detected by slight yellow color in the filtrate. Uncoated
CONPs showed a lower reaction yield of 78.5% due to difficulty in recovering from the MWCO
filter because of their insolubility.

4.1.2. Non-Radioactive synthesis of Zr-CONPs
ICP-OES results for incorporation of non-radioactive zirconium into CONPs are shown in Table
6. The reaction yields become much lower as the percent of zirconium in solution increases.
However, during radiosynthesis, the amount of 89Zr in solution is trace, so the 96% incorporation
at 0.5% was encouraging and indicated a likely high yield for radiosynthesis and warranted
pursuit of radiosynthesis with 89Zr.
Percent Zirconium in solution during CONP synthesis
0.5%
1%
5%

Percent incorporated into CONPs
96%
63%
42%

Table 6: Incorporation of stable zirconium into CONPs. To determine if zirconium could be stably incorporated into
CONPs, solutions of zirconyl chloride were added to the synthesis of DT10-CONP and incorporation was measured
by ICP-OES as percent of original zirconium amount able to be detected in solution with CONPs.

4.1.3. Radiochemical Reaction Yield and Comparison of
Physicochemical Properties of [89Zr]CONPs to CONPs
Radiochemical reaction yields for the incorporation of 89Zr into CONPs were in good accordance
with the non-radioactive yields, with slight reduction for the DT10-based coatings. Yield was
greater than 80% for all coated and uncoated radiosynthesis, with >90% yield for most of the
coated preparations, as seen in Table 6.
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Non-radiolabeled and [89Zr]CONPs’ size and surface charge distribution were characterized by
dynamic light scattering (DLS) and zeta potential (Table 6). The size of CONPs synthesized by
co-precipitation was strongly dependent on the surface coating. Small carboxylate molecules and
low molecular weight polymers, in the case of citrate and PAA, lead to smaller NPs at average of

3.1 and 3.8 nm, respectively. The high molecular weight hydroxyl DT10 polymers lead to larger
CONP sizes, with their reactive functional groups also playing a role in the size, causing them to
produce a size in the range of 6.2 to 14.3 nm. Without polymer or small molecule coating, the
growth of the NPs is not limited by a coating and more NP aggregation occurs, as seen in the
much larger size of uncoated CONPs at around 156 – 163 nm.104 While uncoated CONP samples
were sonicated before DLS measurement, aggregation into larger particles could still be detected
in the uncoated [89Zr]CONPs, showing their tendency to immediately aggregate in water
solution.
The incorporation of 89Zr into the core of CONPs had very little effect on their size and charge.
The DLS size profiles were almost identical for the non-radiolabeled CONPs and [89Zr]CONPs,
as seen in Table 6 and Figure 38. Uncoated non-radiolabeled and [89Zr]CONPs showed similar
size except for 10% aggregation at ~1.1 μm for the uncoated [89Zr]CONPs. The surface charges,
measured as zeta potential, were also very similar across the uncoated and coated CONPs and
[89Zr]CONPs, as seen in Table 6. These results indicate not only that 89Zr incorporation has
negligible effect on CONP synthesis, but that different batches made under the same conditions
have the same physicochemical properties, an important aspect for a reproducible standardized
synthesis.
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Figure 38: DLS measurement of the various coated and uncoated CONPs and [89Zr]CONPs. Size distribution of the
CONPs is reported in terms of number (%), where the y-axis represents percent of total particles that were detected
at that size. All CONPs and [89Zr]CONPs show almost the same distribution of sizes, indicating no effect of 89Zr
incorporation on size.

4.1.

Stability Studies

Stability studies were done to determine how stably 89Zr was incorporated into the core of
CONPs to ensure that radioactive signal represents the nanoparticles. Several methods were
used, including radioactive instant thin layer chromatography (Radio-ITLC), and ultraviolet(UV-) and radioactive HPLC detection of CONP and 89Zr signal, respectively.
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4.1.1. Desferoxamine (DFO) Challenge of [89Zr]CONPs
A desferoxamine (DFO) challenge and molecular weight cut off (MWCO) method was used to
determine 89Zr incorporation into and stability of coated and uncoated [89Zr]CONPs, as seen in
Figure 39. While these results show a significant loss in activity for citrate and DT10-NH2
coated CONPs after 24 hours of incubation with DFO, all other coatings show ≥ 80% retention
of activity after 24 hours, indicating good stability of 89Zr in the nanoparticle. The loss of activity
can be attributed to the harshness of the chelation test that does not reflect conditions in the body.
Higher loss of activity by citrate and DT10-NH2 coated [89Zr]CONPs may be due to chelation of
89

Zr to the surface coating, which is more easily removed by DFO, especially in the case of

citrate coated [89Zr]CONPs due to EDTA, another chelator, used in the surface coating. These
values are also consistent with other studies that use desferoxamine (DFO) as a chelating agent
and show decrease in RCP by as much as 55% when challenged with
diethylenetriaminepentaacetic acid (DTPA).105

Figure 39: [89Zr]CONP Stability – Desferoxamine (DFO) Challenge. DFO, a strong chelator, was incubated with
the various coated and uncoated [89Zr]CONPs using a molecular wright cutoff (MWCO) method by which >95% of
89
Zr bound to DFO passes through the filter, while 89Zr labeled CONPs are retained. Results show that 89Zr was
successfully incorporated into the core of CONPs, with some coatings showing less stability, notably citrate and
DT10-NH2 coated [89Zr]CONPs.
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4.1.2. Radio- and UV-HPLC of [89Zr ]CONPs
A radio- and UV-HPLC method was used to determine the coincidence of signal from CONPs
and 89Zr. Free 89Zr as 89ZrCl2 does not elute through the column, so analysis of RCP could not be
done by this method. However, HPLC results did show that the radioactive signal detected
matched exactly with the UV signal of CONPs (254 nm), demonstrating the proof of concept that
radioactive signal represents the nanoparticle location, as seen in Figure 40. In vivo stability of
[89Zr ]CONPs was also demonstrated by analyzing blood samples at 2 hours post i.v. injection,
seen in Figure 41, and showing the same coincidence of UV and radioactive signal and
validating in vivo signal detection representing CONP distribution.
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Figure 40: HPLC UV and radioactivity retention times of [89Zr]CONPs. Uncoated (A) [ 89Zr]CONPs and citrate
(B), DT10-NH2 (C), DT10-PEG (D), DT10-SB (E) and PAA (F) coated [89Zr]CONPs were injected into HPLC and
detected by UV (254nm) of CONP and radioactivity of 89Zr.
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Figure 41: HPLC UV and radioactivity retention times for 2 hour plasma samples from mice i.v. injected with
[89Zr]CONPs. Citrate (A), DT10-NH2 (B), DT10-PEG (C), DT10-SB (D) and PAA (E) coated [89Zr]CONPs were
i.v. injected into C57B/6 mice and plasma samples were taken at 2 hours. Plasma samples were injected into HPLC
and detected by UV (254nm) of CONP and radioactivity of 89Zr. The plasma sample from the mouse injected with
uncoated [89Zr]CONPs did not have enough radioactivity for detection.
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4.2.

Autocatalytic Activity of CONPs and [89Zr]CONPs

In order to determine that the various coated CONPs and [89Zr]CONPs retain redox cycling
ability, and autocatalytic assay was done with H2O2. The autocatalytic properties of CONPs are
measured in a reaction in H2O2 as the color change of CONPs reflects their change in oxidation
state, recorded as absorbance at 420 nm by a well plate reader. CONPs react quickly with H2O2
and gradually return to their original oxidation state over the course of a few days, which was not
affected by the coating of CONPs, as seen in Figure 42, and even shows that the uncoated
CONPs did not return to baseline as effectively as the coated CONPs. As previously reported,
the reduction process of intrinsically radiolabeled CONP was observed to be faster than the nonradiolabeled CONPs which reflects the improved recycling of radioisotope-doped CONPs.52 The

Figure 42: CONPs’ and [89Zr]CONPs’ cycling redox reaction with H2O2. H2O2 was added to 0.5 mg/mL solutions
of non-radiolabeled and 89Zr labeled uncoated CONPs (A) and citrate (B), DT10-NH2 (C), DT10-PEG (D), DT10SB (E) and PAA (F) coated CONPs and [89Zr]CONPs. Absorbance was monitored at 420 nm to test for their ability
to reduce H2O2. Absorbance was normalized to initial solution absorbance (0%) and to highest absorbance after
reaction (100%) and was monitored over 5 days. Zero percent corresponds to CONPs being primed for radical
scavenging, whilst 100% represents CONPs being fully oxidized. Initial measurements were taken before H 2O2
addition, immediately after and 1 hour after addition. On day 6, H2O2 was again added to demonstrate true redox
cycling with increased absorbance similar to initial reaction. (Mean ± SEM, n=3)
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reason for the apparent improvement in redox reaction cycling of intrinsically radiolabeled
CONPs is interesting and could possibly be due energy absorption, emitted from the
radioisotope. This could be a means by which to increase the rate of conversion of Ce4+ to Ce3+
within radiolabeled CONP and increase redox reaction capacity. Interestingly, the same
phenomenon was observed when the CONPs were exposed to UV light, reducing the time for
recovery from days to hours, further supporting the theory that absorbing forms of
electromagnetic energy affect their redox properties. Figure 42 also shows that H2O2 was added
again at day 6 to ensure the ability to repeatedly perform redox reactions. All coated and
uncoated CONPs showed true redox cycling with similar shifts in absorbance compared to the
first addition of H2O2.

4.2.1. pH Dependent Autocatalytic Activity
To determine if pH could affect the reaction of CONPs with H2O2, the autocatalytic reaction was
repeated with PAA-CONP in buffered solutions of 6.6, 7.0, and 7.4, as seen in Figure 43. PAACONP showed a slight decrease in reaction with H2O2 at pH 7.0, though not significant (142% vs
130%, p = 0.064). At pH 6.6 PAA-CONP showed a signification 49% decrease in reaction with
H2O2 (142% vs 72%, p < 0.0001). This shows that CONPs have a reduced ability to act as an
antioxidant with a very small shift towards acidic pH, indicating a possible mechanism by which
they are unable to protect cancerous tissue due to the acidity of the tumor microenvironment.
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Figure 43: PAA-CONPs’ pH dependent redox reaction with H2O2. H2O2 was added to 0.5mg/mL solutions of PAACONP, buffered to pHs of 7.4, 7.0, and 6.6. The initial increase is absorbance, monitored at 420 nm, was measured,
indicating the change in oxidation state of surface cerium from Ce 3+ to Ce4+. Compared to PAA-CONPs at pH 7.4, at
pH 7.0 they showed a small but not significant decrease in reaction (142% vs 130%, p = 0.064), while at 6.6 they
showed a significant decrease (142% vs 72%, * p < 0.0001), indicating a strong effect of pH on redox ability,
decreasing as pH decreases. (Mean ± SEM, n=6)

4.3.
Cell Viability of COLO-205 and HCT-116 with Increasing
Concentrations of CONPs and [89Zr]CONPs
The toxicity of CONPs and radiolabeled CONPs has been shown to be very low in vitro.52,70 To
ensure that toxicity was not increased by
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Zr, [89Zr]CONPs were incubated in increasing

concentrations with two cell lines and viability was determined following 24hr incubation, seen in
Figure 44. For a decrease greater than 5%, toxicity in COLO-205 colon cancer cells was only seen
with [89Zr]CONP-PAA at the highest concentration of 120ug/mL, while in HCT-116 colon cancer
cells only the [89Zr]CONP-citrate and [89Zr]CONP-PAA showed toxicity, again only at the highest
concentration. None of the other coatings showed toxicity over 5% in these cell lines up to the
highest [89Zr]CONP concentration tested.
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Figure 44: [89Zr]CONPs’ effect on cell viability. [89Zr]CONPs were incubated in increasing concentrations from 1
to 120 μg/mL in two colon cancer cell lines, COLO-205 (A) and HCT-116 (B), and cell viability measured using
Cell Titer-Glo Assay. Only citrate (HCT-116) and PAA (COLO-205 and HCT-116) coated CONPs showed
significant toxicity, and only at the highest concentration tested of 120 μg/mL (Mean ± SEM, n=3, * p < 0.05)
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4.4.

Comparison of Uptake of Coated and Uncoated

[89Zr]CONPs in COLO-205 and HCT-116 in Different pH Media
Uptake of PAA-[89Zr]CONPs in COLO-205 and HCT-116 cells was seen to be altered by the pH
of the growth media in an inconsistent manner when comparing the two cell lines, seen in Figure
45. For COLO-205, uptake was similar at pH 7.4 and 7.0 (p = 0.343), but decreased significantly
by 89% at pH 6.6 (p = 0.0006). For uptake of PAA-[89Zr]CONPs in HCT-116 cells, uptake was
seen to decrease significantly by 23% in pH 7.0 media compared to pH 7.4 media (p = 0.012).
However, at pH 6.6 the uptake increase by 40% compared to pH 7.4 (p = 0.008).

Figure 45: Uptake of PAA-[89Zr]CONPs in COLO-205 and HCT-116 cells. Uptake of PAA-[89Zr]CONPs was
significantly decreased at pH 6.6 in COLO-205 cells, compared to pH 7.0 and 7.4 (* p = 0.0006). However, uptake
changes were not consistent across cell lines, with HCT-116 cells showing decreased uptake a pH 7.0 (** p =
0.012), and increased uptake at pH 6.6 (*** p = 0.008) when compared to pH7.4. (Mean ± SEM, n=3)
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4.5.

pH Dependent Radioprotection of CONPs in HCT-116 cells

Clonogenic assay results for HCT-116 cells irradiated or treated with CONPs before irradiation
in pHs of 7.4 and 7.0 showed a marginal difference in radioprotection, seen in Figure 46. PAACONP pre-treatment before irradiation for cells in pH 7.4 media showed a slight increase in %
plating efficiency compared to cells only irradiated, though not significant (15% vs 13.1%, p =
0.068). Pre-treatment with PAA-CONPs before irradiation in pH 7.0 media showed no change in
% plating efficiency, indicating no protection of cancer cells from radiation at pH 7.0 (2.0% vs
2.2%, p = 0.333). This study warranted an in vivo examination of whether normalization of the
pH microenvironment in tumor would cause CONPs to have radioprotection that is absent at
lower pH.

Figure 46: Change in % plating efficiency of irradiated HCT-116 cells when incubated with PAA-CONP and in
different pH media. Clonogenic assay of HCT-116 cells irradiated with 5 Gray in pH 7.4 media showed an increase
in % plating efficiency when incubated with PAA-CONP when compared to cells only irradiated, though not
significant (p = 0.068). When incubated in pH 7.0 media, there was no difference in % plating efficiency when
comparing cells irradiated with PAA-CONP versus irradiated alone (p = 0.333). (Mean ± SEM, n=3, * p < 0.01, **
p < 0.05)
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4.6.
Clonogenic Assay of PAA-CONP Treated and Irradiated
Xenograft Tumors
Control and PAA-CONP pretreated mice with HCT-116 xenograft tumors given whole body
dose of 10 Gray had their tumors removed and plated for clonogenic measurement in comparison
to control and PAA-CONP only treated mice. PAA-CONP alone showed no effect on % plating
efficiency compared to control (p = 0.10), but both irradiated and PAA-CONP treated and
irradiated tumors showed significant decrease in % plating efficiency (p < 0.00001), as seen in
Figure 47. Further, PAA-CONP pre-treatment showed enhanced killing of tumor, with a
significant decrease in % plating efficiency compared to radiation alone (p < 0.00001). This
indicates possible radiosensitization where CONPs may enhance the killing effects of radiation
in tumor, as also seen in previous research (Figure 9).9

Figure 47: Change in % plating efficiency of irradiated xenograft HCT-116 tumors when administered PAA-CONP.
Clonogenic assay of HCT-116 xenograft tumors irradiated with 10 Gray showed a significant decrease in % plating
efficiency both when pre-treated with PAA-CONPs and with radiation alone as compared to control tumors (both p
< 0.00001). PAA-CONP treatment alone showed no effect on % plating efficiency compared to control (p = 0.10).
Compared to tumors only irradiated, PAA-CONP treated irradiated tumors showed further decrease in % plating
efficiency (p < 0.00001). This may indicate a radiosensitization by CONPs. (Mean ± SEM, n=6, * p < .00001)
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4.7.

Biodistribution

Biodistribution results are given in terms of ex vivo gamma counts of major organs and images
and video of PET imaging of uncoated and coated [89Zr]CONPs. 89ZrCl2 was also examined to
ensure results were not due solely to 89Zr signal separated from the nanoparticles.

4.7.1. Ex Vivo Gamma Counting Results
Ex vivo biodistribution for all uncoated and coated [89Zr]CONPs at 2 and 24 hours is shown in
Figure 48. The general PET imaging profiles of the coated and uncoated CONPs is in
accordance with the ex vivo biodistribution data. Both imaging and ex vivo analysis showed the
majority of the uncoated [89Zr]CONPs in the lung, with elevated uptake in the liver and spleen.
The coated [89Zr]CONPs showed a much more general distribution to most organs, with uptake
in the liver and spleen, with preferential kidney uptake for citrate and PAA coated [89Zr]CONPs.
Comparing uptake in the liver and spleen at 24 hours, [89Zr]CONP-PAA showed the least uptake
(Figure 49A&B). [89Zr]CONPs’ also show significant 24 hour uptake in the gallbladder and
feces, indicating hepatobiliary excretion, with [89Zr]CONP-DT10-SB showing particularly high
excretion by this method (Figure 49C&D).
Figure 50 compares the uptake of [89Zr]CONPs in several major organs and tumor. Uncoated
[89Zr]CONPs show highest uptake in the lungs and heart, but the least in every other organ.
Among the coated [89Zr]CONPs, PAA shows the most consistent high uptake in all organs.
[89Zr]CONP-citrate and [89Zr]CONP-PEG show highest uptake in tumors.
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Figure 48: Uptake of [89Zr]CONPs in all excised tissues. Mice tail vein injected with uncoated [ 89Zr]CONP (A),
[89Zr]CONP-Citrate (B), [89Zr]CONP-DT10-NH2(C), [89Zr]CONP-DT10-PEG (D), [89Zr]CONP-DT-SB (E) and
[89Zr]CONP-PAA (F) were sacrificed at 2 and 24 hours post-injection and tissues were weighed and gamma counted
and percent injected dose per gram (%ID/g) was determined. Organs are presented in order of highest to lowest
uptake (at 2 hours), from left to right. (Mean ± SEM, n=3-6)
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Figure 49: [89Zr]CONPs’ reticuloendothelial uptake and hepatobiliary clearance at 24 hours. Uptake in the organs of
the reticuloendothelial system, liver (A) and spleen (B), at 24 hours is compared as a function of [ 89Zr]CONP
coating. Hepatobiliary clearance through the gallbladder (C) and feces (D) at 24 hours is also compared. Uptake is
presented in order of highest to lowest uptake, from left to right. (Mean ± SEM, n=3-6)

Figure 50: Comparative uptake of [89Zr]CONPs in major organs and tumor at 24 hours. Uptake in the lungs (A),
kidney (B), heart (C), stomach (D), colon (E) and tumor (F) at 24 hours is compared as a function of [ 89Zr]CONP
coating. Uptake is presented in order of highest to lowest uptake, from left to right. (Mean ± SEM, n=3-6)
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4.7.2. Whole Body Activity of Mice Injected with [89Zr]CONPs
Whole body radioactivity of C57BL/6 mice injected with the various coated and uncoated
[89Zr]CONPs showed high retention in all but PAA-[89Zr]CONPs, as seen in Figure 51. This is
likely due to the high uptake in the reticuloendothelial system and very slow excretion through
the feces. However, PAA-[89Zr]CONPs’ show excellent pharmacokinetics with high renal
clearance of 75% between 2 and 4 hours. More importantly, this clearance does seem to affect
the uptake of PAA-[89Zr]CONPs in other tissues, where it can be seen to be taken up as much or
more than all the other coated and uncoated [89Zr]CONPs in most tissues.

Figure 51: Excretion of [89Zr]CONPs over the course of one week. High doses of the various coated and uncoated
[89Zr]CONPs were i.v. injected into C57BL/6 mice and total body radioactivity was monitored over the course of
one week. All coated and uncoated [89Zr]CONPs except PAA-[89Zr]CONPs showed high retention of activity,
indicating little excretion of the nanoparticles. However, PAA-[89Zr]CONPs showed a 75% reduction in activity
between 2 and 4 hours, likely all in the urine according to PET imaging and ex vivo biodistribution data. During the
course of the experiment, all mice injected with citrate[ 89Zr]CONPs died on day 3, and two mice injected with
DT10-NH2-[89Zr]CONPs died on day 3 and 5, indicating toxicity at the high dose (~40 mg/kg) given. All other mice
showed good tolerance of the high dose. (Mean ± SEM, n=3)
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4.7.3. In Vivo PET-CT Imaging of [89Zr]CONPs
PET-CT dynamic scans were done for each type of [89Zr]CONP, which images the distribution
of the nanoparticles during the first hour after injection. Videos of each [89Zr]CONP dynamic
scan can be found in the Supplementary Video Section. Maximum intensity projections of the
dynamic scans at times between 1 and 60 minutes, after injection, are presented in Figure 52.
The majority of the activity of the uncoated [89Zr]CONPs immediately shows in the lungs. Over
the next hour, uptake of the uncoated [89Zr]CONPs increases in the liver and spleen, which
indicates uptake by the reticuloendothelial system (RES) through phagocytosis, commonly to NP
biodistribution.36,37 Unlike uncoated [89Zr]CONPs, all of the coated [89Zr]CONPs showed blood
flow driven distribution at least for the first minute. Liver and spleen uptake are also seen across
all of the coated [89Zr]CONPs. Among the coatings, the PAA and citrate were unique due to their
ability to be cleared by the kidneys into the urine. This clearance was apparent within the first
minute for [89Zr]CONP-citrate, with the kidneys having higher uptake at this time, and
[89Zr]CONPs appearing in the urine by 5 minutes. For [89Zr]CONP-PAA, kidney uptake and
urine clearance are seen by 30 minutes. Of the DT10-based coatings, DT10-NH2, after showing
distribution in the blood stream for the first minute, only shows concentrated activity in the liver
and spleen after 5 minutes. The DT10-SB coating shows continuous blood circulation over the
first hour, but also shows concentrated signal in the liver and spleen after 5 minutes. The DT10PEG coating showed undiminished blood distribution over the first hour, with much less signal
from the liver and spleen.
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Figure 52: Maximum intensity projections from PET-CT dynamic scans after injection of [89Zr]CONPs. Mice were
tail vein injected with uncoated [89Zr]CONP (A), [89Zr]CONP-Citrate (B), [89Zr]CONP-DT10-NH2(C), [89Zr]CONPDT10-PEG (D), [89Zr]CONP-DT-SB (E), [89Zr]CONP-PAA (F) and the distribution was imaged by PET-CT over
the course of one hour. Images were rotated to best show major organ uptake.
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4.7.4. Analysis of 89ZrCl2 Biodistribution
To further validate use of radioactive 89Zr as an inherent signal for CONP detection, 89ZrCl2 was
i.v. tail vein injected and PET-CT and ex vivo biodistribution were performed, as seen in Figures
53 and 54. The results were consistent with previous 89ZrCl2 biodistribution studies.106 The
distribution of 89ZrCl2 was significantly different compared to the distribution of any the
[89Zr]CONPs. This demonstrates the radioactive signal was indicative of [89Zr]CONP
distribution and not that of free 89Zr.

Figure 53: Uptake of [89Zr]-Chloride in all excised tissues. Mice tail vein injected with [ 89Zr]-Chloride were
sacrificed at 2 and 24 hours post-injection and tissues were weighed and gamma counted and percent injected dose
per gram (%ID/g) was determined. Organs are presented in order of highest to lowest uptake (at 2 hours), from left
to right. (Mean ± SEM, n=3)

Figure 54: Maximum intensity projections from PET-CT dynamic scans after injection of [89Zr]-Chloride. A mouse
was tail vein injected with [89Zr]-Chloride and the biodistribution was imaged by PET-CT over the course of 1 hour.
Images were rotated to best show major organ uptake.
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4.7.5. Other Routes of Administration of [89Zr]CONPs
Other than i.v. administration of [89Zr]CONPs, i.p. and oral administration routes were also
tested. The distribution results of both i.p. and oral administration were poor, with the
[89Zr]CONPs not leaving the intraperitoneal cavity after i.p. injection and passing through the
gastrointestinal tract with minimal uptake after oral administration. Representative images of
DT10-NH2 and PAA coated [89Zr]CONPs show the lack of uptake at 24 hours (Figure 55) and
ex vivo biodistribution showed uptake no higher than one percent injected dose per gram in any
organs from either administration route (data not shown).

Figure 55: Maximum intensity projections from PET-CT scans 24 hour after i.p. injection and oral gavage of [89Zr]CONP-PAA and [89Zr]-CONP-DT10-NH2. Mice were i.p. injected or given oral gavage of PAA (A, C) and DT10NH2 (B, D) [89Zr]-CONPs and the biodistribution was imaged by PET-CT 24 hours after injection/gavage. Images
were rotated to best show major organ uptake.

4.8.
[18F]FDG Uptake Irradiated Colon Tumors with and without
CONP Pre-Treatment
Analysis of [18F]FDG images before and after radiation treatment with or without CONP pretreatment showed slight differences in tumor response based on the type of CONP given. While
none of coatings showed significant difference in reduction of functional tumor volume
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compared to radiation alone, all but one CONP variation showed less tumor control overall, as
seen in Figure 56. Citrate CONPs, DT10-PEG CONPs, and uncoated CONPs pre-treatment
before irradiation all showed less tumor functional volume reduction compared to irradiation
alone. Reduction of tumor functional volume from radiation alone was 54%, compared to 34%
for citrate CONP (p = 0.067), 27% for DT10-PEG (p = 0.056), and 28% for uncoated CONP (p =
0.069). While none show significance due to the large variation in tumor response, it appears that
these variations of CONP seem to show some protection of the tumor from radiation, which
would prevent expected tumor control and would reduce therapeutic index. On the other hand,
PAA-CONP showed virtually no difference in tumor functional volume reduction compared to
irradiation alone (54% vs 53%, p = 0.39). While it cannot be ruled out that the other variations of
CONPs do not show radioprotection in tumor, PAA-CONP is the most likely among the tested
CONPs to lack radioprotection of tumor.

Figure 56: Analysis of spontaneous colon tumor response to radiation with and without CONPs as measured by
[18F]FDG PET imaging before and two weeks after radiation. All irradiated tumors showed a decrease in functional
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tumor volume, but only PAA-CONP pre-treatment showed the same level of tumor control compared to irradiation
alone. (Mean ± SEM, n=3-5)

4.9.
Colon Tissue Response to Radiation with and without
CONP or Amifostine Pre-Treatment
C57BL/6 mouse colons were irradiated by the SARRP system with or without the various CONP
or amifostine pre-treatment. Colons were harvested 4 hours after irradiation, sectioned, and
stained on slides. The apoptotic index was measured by comparing the ratio of staining for
apoptosis and background nuclear staining, as seen in Figure 57. The apoptotic index extremely
low in untreated mice, as expected, and was highest in mice that were only irradiated. It was
significantly decreased in all treated mice (citrate-CONP p = 0.024, PAA-CONP p = 0.047,
DT10-PEG-CONP p = 0.025, uncoated CONP p = 0.034, and amifostine p = 0.039). These
results demonstrate that all coated CONPs retain the ability to be radioprotective, and show the
same level of protection as a clinical radioprotective drug.

Figure 57: Apoptotic index in the colons of control mice and mice 4 hours after irradiation with or without CONP
or amifostine pre-treatment. The apoptotic index of mouse colons was measured by ex vivo imaging of sections of
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colon stained for apoptosis with a background nuclear stain for quantification by ratio measurement. Control colons
showed very low apoptosis, while highest was seen in colons only irradiated. All pre-treatments showed decrease in
apoptosis, indicating radioprotection, including citrate-CONP p = 0.024, PAA-CONP p = 0.047, DT10-PEG-CONP
p = 0.025, uncoated CONP p = 0.034, and amifostine p = 0.039. (Mean ± SEM, n=3-6, * p < 0.05)

4.10.

pH Measurement of Xenograft Tumors

Before response of CONPs’ radioprotection to tumor normalization could be measured, the
method of tumor normalization needed to be verified. Three methods of pH measurement were
used to determine the normalization effects of sodium bicarbonate on tumor pH. pH mapping by
MRI CEST methods were developed and used to perform in vivo pH measurement, while the two
other methods, pH needle probe measurement and SNARF-5F fluorescent imaging, required
sacrifice of the animals and are less desirable approaches for pH measurement.

4.10.1.

MRI CEST pH Mapping

pH mapping using MRI CEST imaging and analysis methods showed change in increase in pH
in the tumor volume in response to bicarbonate therapy, as seen in Figure 58. The bicarbonate
treated mouse shows that many areas in the tumor have increased in pH, validating the
normalization effects of sodium bicarbonate treatment.

Figure 58: Map of tumor pH based on MRI CEST imaging and analysis, overlaid on T 2-weighted background
image. HCT-116 xenograft bearing mice without (left) and with (right) sodium bicarbonate pre-treatment (1 M, 700
μL, oral) were imaged using a CEST protocol after iopamidol injection. The untreated mouse shows a low pH
through the tumor volume, while the treated mouse shows increase in pH interspersed with low pH in the tumor
volume. Areas without enough concentration of iopamidol for pH determination were removed.
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4.10.2.

Ex vivo Validation of pH with pH Needle Probe and

SNARF-5F Fluorescence Imaging of pH
Ex vivo analysis of tumor pH was done with a pH needle electrode probe, which was inserted
into the tumors of HCT-116 xenograft bearing mice for direct pH measurement. The tumor pH of
untreated animals ranged from 6.82 to 7.19. pH of HCT-116 xenograft tumors was also
measured in mice three hours after sodium bicarbonate treatment. These tumors showed a much
narrower range of pH, 7.20 to 7.33, and was significantly higher than untreated, as seen in
Figure 59 (6.92 vs 7.24, p < 0.00001).

Figure 59: Needle pH probe direct measurements of tumor pH of untreated and sodium bicarbonate treated mice.
Untreated mice showed a wider variation and significantly lower pH than mice treated with sodium bicarbonate (* p
< 0.00001), indicating successful normalization of tumor microenvironment by sodium bicarbonate treatment.
(Mean ± SEM, n=5-6)
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4.10.1.

Tumor pH Imaging by SNARF-5F

Ex vivo tumor sections from mice injected with SNARF-5F were imaged and spectrally unmixed
by using the spectrums of the reference SNARF-5F pH solutions. Images revealed heterogeneity
with areas of low pH in untreated tumors, while tumors from mice treated with sodium
bicarbonate showed much more homogenous pH that was closer to physiological pH of 7.4, as
seen in Figure 60.

Figure 60: Ex vivo SNARF-5F imaging of tumor sections of untreated mice and sodium bicarbonate treated mice.
Xenograft tumors that were sectioned from untreated (left) showed much more heterogeneity and lower pH than
tumors from mice treated with sodium bicarbonate (right).
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4.11.
Effects of Tumor pH Normalization on PAA-CONPs
Radioprotection of Xenograft Tumors
Volume change of irradiated mouse xenograft tumors with and without radiation and pretreatment combinations of sodium bicarbonate alone, PAA-CONP alone, and sodium bicarbonate
and PAA-CONP were measured by MRI before and two weeks after treatment, as seen in Figure
61. All radiation treatment groups saw significantly less increase in tumor volume than control
mice except in sodium bicarbonate and PAA-CONP pre-treated mice (IR only p = 0.039, Bicarb
+ IR p = 0.048, PAA-CONP + IR p = 0.039, Bicarb and PAA + IR p = 0.060). While the
difference in p-values are small, the significant difference in tumor response for non-normalized,
lower pH tumors treated with PAA-CONP before radiation and lack of significant difference in
tumor response for normalized, higher pH tumors supports the theory that change in pH alters
CONPs’ radioprotective properties in vivo.
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Figure 61: Percent increase in xenograft tumor volume in control and irradiated tumors with PAA-CONP alone,
sodium bicarbonate alone, or sodium bicarbonate and PAA-CONP pre-treatment, as measured by MRI. MRI images
were taken before and two weeks after treatment and volumes, measured in ImageJ by VolumEst, were compared in
mice without treatment, irradiated only, pre-treated with sodium bicarbonate before irradiation, pre-treated with
PAA-CONP before irradiation, or pre-treated with both sodium bicarbonate and PAA-CONP before irradiation. All
irradiated tumors saw a significant decrease in tumor growth compared to control except sodium bicarbonate and
PAA-CONP pre-treatment (IR only p = 0.039, Bicarb + IR p = 0.048, PAA-CONP + IR p = 0.039, Bicarb and PAA
+ IR p = 0.060). These results indicate radioprotective properties of CONPs may be absent in the acidic pH of the
tumor, but return when the pH is normalized. (Mean ± SEM, n=3, * p < 0.05)
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5. Chapter 5 – Discussion

5.1.

Coated and 89Zr Labeled CONPs as Methods to Improve

and Study Pharmacokinetics
89

Zr is an attractive PET radioisotope with increasing clinical use in immuno-PET imaging of

receptor targeting antibodies and peptides.107–110 It has a useful half-life of 78 hours, suitable for
both short and long term kinetic studies. Preclinical and clinical research with 89Zr has been
enhanced by the availability of the radioisotope from widely available medical cyclotrons.
Although we have incorporated various radioisotopes into the CONP core, the use 89Zr allows
for high sensitivity PET imaging and the potential for clinical translation. Doping of nonradioactive zirconium into the core of CONPs (with up to 15% efficiency), has been previously
reported as very stable, with the retention of cerium oxide’s native cubic fluorite structure.111 Our
results also showed good incorporation of stable zirconium, especially at 0.5%. These procedures
used a much higher concentration of Zr, compared with the trace amount of 89Zr incorporated
into [89Zr]CONPs radiosynthesis, which is on the order of 10 – 100 ng. While Radio-ITLC
showed some instability of citrate-, PAA-, and DT10-SB coated [89Zr]CONPs in retention of 89Zr
activity, the results were comparable to other 89Zr compounds used for in vivo studies. UV- and
radio-HPLC analysis showed that the radioactivity is associated with the CONP UV retention
time from aqueous and in vivo blood samples, demonstrating good stability of [89Zr]CONP ex
vivo. This validates the use of the 89Zr radioactive signal to report on the overall CONP
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biodistribution. We have previously tested several materials, as CONP coating ligands, including
glucose, cyclodextran, mannose, maltose, dextran-T10, ascorbic acid and dehydroascorbic acid,
but all were deemed unworthy for pursuit due to low reaction yields or poor stability (data not
shown). The investigated ligands in this paper all showed very high reaction yields and good
stability over months to years, with the notable exception of citrate coated CONP, which had a
stable shelf life of about two weeks before showing signs of aggregation. The functionalization
of DT10 with sulfobetaine, amine and polyethylene glycol not only served to better stabilize the
CONPs, but also allowed the determination of surface charge effects on CONP biodistribution,
having negative, positive and near neutral surface charge, respectively.

5.2.

Comparison of coatings and CONPs vs [89Zr]CONP

Surface coatings on CONPs were able to change the physicochemical and biodistribution
properties of CONPs while retaining their redox properties and low toxicity. 89Zr labeling was
intended to not disrupt any of these properties, allowing for detection of the nanoparticles
without affecting any other properties. This project was successful in achieving these aims, as
described below.

5.2.1. Size and surface charge
Surface coating showed an excellent ability to reduce the size of CONPs, impart a surface charge
on the nanoparticle, and stably dissolve in water and saline. The hydrodynamic size and zeta
potential surface charge of coated and uncoated CONPs and their counterpart [89Zr]CONPs were
shown to be almost identical.
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5.2.2. Autocatalytic activity
It was important to determine if there were any effects of the coating on the redox properties of
CONPs so that they can still exert their anti-oxidant properties in a biologically relevant
environment. The reaction of the coated CONPs with H2O2 and their cycling to their original
oxidation state was not hindered, indicating that the coatings were not affecting the cerium oxide
core from reacting with radicals in solution, nor its ability catalytically to cycle back to its
original oxidation state.
The coated CONPs returned to baseline much more effectively than the uncoated CONPs. The
apparent better recycling of the coated CONPs is possibly due to increased surface-area-tovolume ratio of smaller NPs, leading to an increased ability to react with H2O2 and cycle back.
The addition of H2O2 on day 6 served to demonstrate true recycling of redox properties where the
CONPs are able to react again with H2O2 with similar results to the initial reaction.
[89Zr]CONPs showed an enhanced cycling of redox ability, possibly due to energy imparted to
the cerium on the surface by the radioactive isotope. This was further confirmed with UV light
showing the same enhancement of redox cycling, though more studies need to be done to
confirm this hypothesis.

5.2.3. Toxicity
Unlike other metal based NPs, CONP has been demonstrated to have very low toxicity in a
number of studies.112 Cell toxicity data showed the 89Zr CONPs are non-toxic up to very large
concentrations. The toxicity of the PAA coated CONPs has been improved from previous studies
that showed toxicity as low as 40 μg/ml.52 The modified synthesis of coated CONPs, using a
reduced ratio of coating molecule to cerium salt in the starting solution, resulted in significantly
less toxicity of PAA CONPs, sowing toxicity only at the highest concentration tested at 120
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μg/mL. In vivo toxicity was also indirectly monitored during the high dose injections (~40
mg/kg) required for PET imaging and whole body radioactivity monitoring. Only citrate- and
DT10-NH2 showed lethality at these doses, and appeared to be well tolerated in all other CONPs.

5.2.4. In Vivo Biodistribution
Through following the distribution of [89Zr]CONPs, we were able to determine how the coated
[89Zr]CONPs compared to the uncoated in terms of organ uptake and retention. PET-CT imaging
of [89Zr]CONPs showed difference in biodistribution between the coated and uncoated NPs
which was apparent by the first minute after i.v. injection. The uncoated [89Zr]CONPs showed
immediate distribution almost exclusively to the lung, with later increased uptake by the liver
and spleen. It is most likely that the significant lung uptake of the uncoated [89Zr]CONPs is due
to aggregation to micrometer particles that become lodged in the capillary bed of the lungs on the
first pass, similar to the lung handling of the lung imaging agent, 99mTc macroaggregated
albumin (99mTc-MAA).113 This likely also explains why uncoated [89Zr]CONPs have the highest
uptake in the heart, again due to trapping after first pass following i.v. injection.
The images/video of the dynamic scans of the coated [89Zr]CONPs show significant differences
in distribution. The citrate, PAA and DT10-PEG coated [89Zr]CONPs were able to avoid
immediate uptake by the RES organs of liver and spleen. DT10-NH2 and DT10-SB coated
[89Zr]CONPs showed high uptake in these organs after only 5 minutes. The strong positive and
negative charge, respectively, of these coatings may make it easier for the endocytotic cells of
the RES to sequester them from circulation, while the neutral coating of DT10-PEG allows
longer escape from RES.51 The PAA coated [89Zr]CONPs were best able to avoid uptake by the
RES, showing the lowest uptake in both the liver and spleen at 24 hours.
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Renal clearance was enhanced in the PAA and citrate coated [89Zr]CONPs. With a
hydrodynamic size less than 5.5 nm, citrate and PAA coated [89Zr]CONPs were able to be
cleared through renal glomerular filteration.114 The DT10 based coatings were above the size
threshold for renal clearance, so they had minimal clearance through the urine. [89Zr]CONPcitrate renal clearance began almost immediately, with high uptake in the kidneys at 1 minute
and appearance in the urine at 5 minutes. There was almost no evidence of activity in the urine at
2 hours post injection, indicating very rapid renal clearance. [89Zr]CONP-PAA showed renal
clearance by 30 minutes and a slightly prolonged clearance, with activity still detected in the
urine at 2 hours, but mostly cleared by 24 hours. Hepatobiliary clearance of [89Zr]CONPs was
also seen, with uptake in the gallbladder, which empties into the intestines and is cleared by the
feces. [89Zr]CONP-DT10-SB especially showed this method of excretion, with the highest
activity in the gallbladder and feces at 24 hours.
The uptake of the [89Zr]CONPs in the major organs is important to note, as these organs are
potential targets for protection from oxidative damage. The high uptake of uncoated
[89Zr]CONPs in the lung and heart may mean they are good candidates for protection of those
organs, but may also lead to prolonged retention and hence could have toxicity implications.
Uncoated [89Zr]CONPs also showed the least uptake in all other major organs. Among the coated
[89Zr]CONPs, PAA showed a more evenly distributed profile pattern in major organs, making it
a good candidate for multiple tissue protection, such as during chemo- or radio-therapy.
Compared to normal tissues, [89Zr]CONP-PAA also showed less uptake in colon tumor; this
could have important implication during chemo- or radio-therapy where tumor protection is not
desirable. Conversely, [89Zr]CONP-citrate showed more uptake in colon tumor compared to
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normal colon. This may indicate that [89Zr]CONP-citrate could be a useful candidate as an
adjuvant anti-cancer agent.72

5.3.

pH Effects on CONPs

pH was shown to have an significant impact on CONPs ability to react with H2O2, reducing its
ability to convert from Ce3+ to Ce4+ in slightly acidic pH, indicating a possible mechanism for
lack of protection in the acidic tumor microenvironment. Uptake was also affected, but the two
cell lines studies showed different results. COLO-205 cells showed decreased uptake only at pH
6.6, compared to pH 7.4 and 7.0, while HCT-116 showed decreased uptake at pH 7.0 but
increase uptake at pH 6.6, compared to cells grown in pH 7.4 media. This may mean that tumor
uptake of CONPs in vivo is unpredictable, but it should not be a concern if they show no
protection in the tumor regardless. Clonogenic assay of cells grown in pH 7.4 showed an
increase in colony formation when incubated in CONPs before being irradiated, though not
significantly. There was no change in colony formation with and without CONPs at pH 7.0,
indicating lower pH may be ideal for preventing radioprotection in tumors.

5.4.

Radiation Protection by CONPs in vivo

CONPs effects on irradiated tissue in vivo were measured in both spontaneous colon tumors and
normal colon tissue, while the effects of tumor normalization on CONPs’ radioprotection were
measured in xenograft tumors.

5.4.1. Spontaneous Colon Tumor Response to CONPs/Radiation
[18F]FDG PET imaging of colon tumors before and after radiation with the variations of CONPs
showed that only PAA-CONP had no noticeable effect on tumor response compared to tumors
that were only irradiated. While not significant compared to radiation alone, citrate-, DT10-PEG,
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and uncoated CONPs showed a less of a decrease in functional tumor volume after irradiation,
indicating less tumor control and possible radiation protection. PAA-CONPs’ lack of protection
of the tumor makes them ideal because a radioprotective drug should not adversely affect the
therapeutic index of radiation therapy.

5.4.2. Protection of Colon Tissue
All of the tested CONPs were able to significantly reduce apoptosis in irradiated colon. Being the
most important aspect of a radioprotective drug, the protection of normal tissue, it was
encouraging to see that all formulations of CONPs showed this property. They also showed the
same level of protection as amifostine, which would likely indicate CONPs ability to compete
with this drug as a radioprotector, and be much more likely for widespread use in the clinic if its
toxicity profile is as low as expected. This is indicative of the fact that the radioprotective
properties are due to the core CONP redox properties while the different coatings influence
cellular and tissue interactions within specific microenvironments.

5.4.1. Effects of pH Normalization in Tumors on CONPs
Radioprotection
Normalization of the pH of irradiated xenograft tumors caused CONPs to not be able to show
significant difference in tumor growth compared to control tumors, indicating that CONPs may
retain their radioprotective properties if the pH of tumors is closer to a physiological pH of 7.4,
while CONP treatment in tumors without normalization showed no radioprotection. This is
supported by studies of the effects of pH on CONPs in solution and in vitro, and shows that
acidic pH may be the reason CONPs show ideal radioprotection in normal tissue which is
reduced in tumors.
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6. Chapter 6 – Conclusions

6.1.

Successful Synthesis of Coated and 89Zr Labeled CONPs

Reaction yields for both coated and 89Zr labeled CONPs were excellent and reproducible, with
~80% or greater yield for all reactions. The coating of and radioisotope incorporation into
CONPs also were shown to be stable and have no effect on their redox properties and toxicity.
Overall, the coating of and radioisotope incorporation into CONPs were shown to have no effect
on their redox properties and toxicity.

6.2.

Coating of CONPs Improves their Biodistribution and

Pharmacokinetics
The type of coating on [89Zr]CONPs greatly alters their biodistribution profile. Compared to
uncoated [89Zr]CONPs, coatings increased the uptake of [89Zr]CONPs in all major organs except
the lungs and heart. Higher uptake in radiation and chemo sensitive organs such as the colon,
heart, lungs and kidneys, will hopefully improve dose-related performance of coated CONPs as a
protective drug. A further indication of the promising clinical application of coated CONPs is the
improved renal clearances of citrate and PAA coated [89Zr]CONPs, and improved hepatobiliary
clearance of [89Zr]CONP-DT10-SB. This was especially noted with PAA-[89Zr]CONPs in the
whole body activity measurements where 75% cleared after only 4 hours. Improved clearance of
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coated [89Zr]CONPs may allow expedited translation to the clinic because clearance minimizes
toxicity and allows radiological imaging, i.e. PET, as exemplified in this study.

6.3.

CONPs Show Similar Radioprotection Compared to

Amifostine
The radioprotection by CONPs in normal colon was shown to be no different than amifostine
pre-treated mice. This demonstration of comparable performance compared to an established
radioprotective drug shows even greater potential for CONPs’ clinical application. It is
especially important to note that the dose given in the clinic and for the mice in this study was
400 mg/kg, which is much higher than the dose, 1 mg/kg cerium weight, given for CONPs.
Although more studies need to be performed, it is hoped that CONPs could see wider adoption
than amifostine due to their likely less toxicity and potential targeted protection.

6.4.

pH Microenvironment of Tumors May Change the

Antioxidant and Radioprotective Properties of CONPs
PAA-CONPs appeared to show some radioprotection in xenograft tumors where pH was
normalized, while absent in untreated tumors, indicating pH as a mechanism by which acidic
tumors may prevent CONP radioprotection. While encouraging, these experiments need to be
repeated due to the wide variation in tumor response and noticeable amount of necrosis in the
tumors, which may have affected volume measurements by MRI imaging. This is a case where
molecular imaging may not always be the best route for measurement of response. Experiments
will have to be repeated, with ex vivo clonogenic assay of tumors being the best candidate
excellent results from this study, as seen in Section 4.6.
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6.5.

PAA-CONPs are a Good Candidate for Translation to the

Clinic
From the studies done, it seems clear that there is one standout among the coated CONPs that
were tested. PAA-CONPs best meet the four criteria set forth for an ideal radioprotective drug.
Their biodistribution shows excellent uptake in normal tissues, with reduced uptake in the
reticuloendothelial system and tumors while being excreted in the urine by 75% after only 4
hours. Their toxicity is low, with in vitro toxicity only at the highest dose tested and in vivo with
a dose forty times the therapeutic dose being well tolerated by mice monitored over the course of
one week. They show good protection of colon tissue measured as reduction of apoptosis, similar
to uncoated CONPs and amifostine, an established radio-protective drug. They do not alter the
radiation response of tumors, so therapeutic index of radiation in tumor should not be affected. It
is therefore the conclusion that PAA-CONPs show the most promise for further investigation as
a radioprotective drug.
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7. Chapter 7 – Future Work

7.1.

Dose-Response Relationship

Based on the research from this project, future studies will likely focus on therapeutic
applications of PAA-CONPs. Studies can be done on dose-response relationship to try to
determine if doses lower than 1 mg/kg cerium weight still have radioprotective effects and can
further reduce concerns for toxicity.

7.2.

Investigate Other Organ Systems

The colon is one of many organ systems at risk during radiation therapy. Currently, there are
plans to study the esophagus, and surrounding tissue such as lungs and heart, for radioprotection
from CONPs. This research would have immediate application in the clinic due to the severe side
effects from radiation therapy of patients with esophageal cancer.

7.3.

Investigate Efficacy in Combination (Chemo and Radiation)

Therapy or Chemotherapy Alone
Like radiation therapy, chemotherapy has severe side effects that decrease patient quality of life.
Many of the mechanisms of chemotherapeutic drugs rely on oxidative stress, which could be
prevented in normal tissues by CONPs with a similar mechanism as in radiation therapy. Due to
PAA-CONPs high uptake in the kidneys and high renal toxicity of many chemotherapeutics,
such as cisplatin, it is planned to determine if PAA-CONPs have a good application in reducing
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chemo renal toxicity. Similarly, doxorubicin has cardiac toxicity, and CONPs will be studied to
determine if they can reduce these side effects. Even just in studying CONPs as a radioprotective
drug, it is still important to determine CONPs effects on chemotherapy because so many patients
undergo combination radiation/chemo-therapy. Preliminary data shows retention of ejection
fraction in rats pre-treated with CONPs before doxorubicin chemotherapy, which is normally
decreased with doxorubicin therapy and is currently under further study.

7.4.

Planning for CONPs use in the clinic

We are currently planning collaboration with the MCV Massey Gastrointestinal Oncology Group
and Dr. Khalid Matin to pursue a clinical trial for CONPs in esophageal cancer patients
undergoing radiation therapy. Before first in human clinical trials, CONPs must go through
preparation and testing. This includes developing an investigational new drug (IND) application
and extensive toxicity studies. While clinical trials are still a ways off, we are currently planning
collaboration with the MCV Massey Gastrointestinal Oncology Group and Dr. Khalid Matin to
pursue a clinical trial for CONPs in esophageal cancer patients undergoing radiation therapy.
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Appendix
Research publications from this work
•

McDonagh PR, Sundaresan G, Yang L, Sun M, Mikkelsen R, Zweit J. Improving
Pharmacological Profile of Cerium Oxide Nanoparticles Through Surface
Modifications: Interrogated by Molecular PET Imaging of [89Zr]CONP.
Nanomedicine: Nanotechnology, Biology and Medicine (in preparation).

•

Hoffman, D. Yang L, Sun M, Sundaresan G, McDonagh PR, Corwin F,
Wang L, Thadigiri C, Zweit J. Intrinsically radiolabeled [59Fe]-SPIONs for dual
MRI/radionuclide detection. Am J Nucl Med Mol Imaging 4, 548–560 (2014).

•

Yang L, Sundaresan G, Sun M, Jose P, Hoffman D, McDonagh PR, Lamichhane
N, Cutler CS, Perez JM, Zweit J. Intrinsically radiolabeled multifunctional cerium
oxide nanoparticles for in vivo studies. J. Mater. Chem. B 1, 1421-1431 (2013).

Conferences and Presentations
•

McDonagh PR, Yang L, Jose P, Sundaresan G, Alam A, Mikkelsen R, Zweit J.
Molecular Imaging Approaches to Study Normal Tissue Protection by MultiFunctional Cerium Oxide Nanoparticles During Radiation Therapy. Poster
presentation at AACR-SNMMI Joint Conference: State-of-the-Art Molecular
Imaging in Cancer Biology and Therapy, Hard Rock Hotel, San Diego, CA,
February 12, 2015.

•

McDonagh PR. Multi-Modal Molecular Imaging to Study Radio-Protection by
Cerium Oxide Nanoparticles. Invited Oral Presentation at the 39th International
Conference and Expo on Advanced Ceramics and Composites, Hilton Daytona
Beach Resort and Ocean Center, Daytona Beach, FL, January 27, 2014.

•

Yang L, Sundaresan G, Sun M, Jose P, McDonagh PR, Zweit J. Intrinsically
Radiolabeled Multifunctional Cerium Oxide nanoparticles for in vivo studies.
Poster presentation at American Association of Cancer Research Annual Meeting
2013, Walter E. Washington Convention Center, Washington, DC, April 9, 2013.
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